Old Dominion University

ODU Digital Commons
Theses and Dissertations in Biomedical
Sciences

College of Sciences

Summer 2008

In Vivo Murine Melanoma Tumor Responses to Nanosecond
Pulsed Electric Field Treatment
Xinhua Chen
Old Dominion University

Follow this and additional works at: https://digitalcommons.odu.edu/biomedicalsciences_etds
Part of the Biophysics Commons, Molecular Biology Commons, and the Oncology Commons

Recommended Citation
Chen, Xinhua. "In Vivo Murine Melanoma Tumor Responses to Nanosecond Pulsed Electric Field
Treatment" (2008). Doctor of Philosophy (PhD), Dissertation, , Old Dominion University, DOI: 10.25777/
r67s-m265
https://digitalcommons.odu.edu/biomedicalsciences_etds/17

This Dissertation is brought to you for free and open access by the College of Sciences at ODU Digital Commons. It
has been accepted for inclusion in Theses and Dissertations in Biomedical Sciences by an authorized administrator
of ODU Digital Commons. For more information, please contact digitalcommons@odu.edu.

IN VIVO MURINE MELANOMA TUMOR RESPONSES TO NANOSECOND
PULSED ELECTRIC FIELD TREATMENT
by
Xinhua Chen
M.D. June 1999, Xinjiang Medical University
Ph.D. May 2006, Zhejiang University School of Medicine
A Dissertation Submitted to the Faculty of
Old Dominion University in Partial Fulfillment of the
Requirement for the Degree of
DOCTOR OF PHILOSOPHY
BIOMEDICAL SCIENCES
OLD DOMINION UNIVERSITY
August 2008

R. Jpmes Swanson (Co-Director)
Karl H. Schoenbach £Co-Director)
Christopher J. Osgood (Member)
StepheVj. Beebe (Member)

ABSTRACT
IN VIVO MURINE MELANOMA TUMOR RESPONSES TO NANOSECOND
PULSED ELECTRIC FIELD TREATMENT
Xinhua Chen
Old Dominion University, 2008
Director: Dr. R. James Swanson
Dr. Karl H. Schoenbach
High intensity nanosecond pulsed electric fields (nsPEF) were applied to melanomaf
tumors to observe functional and structural biological changes and to investigate the
possible molecular mechanisms responsible. An animal model was set up by injecting
B16F10 mouse melanoma cells into SKH-1 mice. A treatment (Tx) of 100 pulses: 300
nanosecond duration; 40 kV/cm field strength; at 0.5 Hz rate were delivered to melanoma
tumors in 120 mice. The nsPEF Tx caused tumor self-destruction with sharply decreased
cell volumes and shrunken nuclei. The apoptotic biochemical tests confirmed nsPEF Tx
induced apoptosis in a time-dependent manner. Examination of gross vessel and microvessel density indicated direct vascular damage to pre-existing vessels and antiangiogenic consequence on neovascular development concomitant with tumor selfdestruction. A five-month survival study on 36 mice showed nsPEF Tx eliminated
tumors with no recurrence to the primary site over the five months. In contradistinction
to ionization, thermal or electroporation Tx, nsPEFs produced broad impacts on the
melanomas in vivo, ranging from DNA fragmentation, caspase activation, nuclear
damage, apoptosis induction, damage to pre-existing intra-tumoral vessels and
neovascular inhibition. These tumor responses were expressed by histological and
biochemical changes in both short and long term trials. The data indicate nsPEF Tx acts
as non-chemical, non-thermal and non-ligand stimulus that can ablate melanomas in vivo.
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CHAPTER I
INTRODUCTION
Melanomas now are the leading cause of death from diseases of the skin. Solid
tumors develop from malignant transformation of melanocytes, which are specialized
pigmented cells residing in the epidermal basement membrane of the skin.1
Malignant melanoma is a very aggressive disease with a high metastatic rate and very
poor overall prognosis. The median survival rate is 6 months and 5-year survival rate is
below 5%. Annually diagnosed cases of melanoma are reported as 53,600 and 7,400
patients died every year, which represents a 15-fold increase over the past four decades
according to the epidemiologic data from American Cancer Society's website.2
The present treatment (Tx) of primary melanoma is surgical excision.3 Complete
surgical removal is the most successful and common treatment for melanoma. Excision
removes the entire melanoma along with a border. In stages II and III melanoma cases
the affected lymph nodes also need to be removed. Such extensive incisions through the
dermis cause scarring on the skin.4 However nsPEF Tx kills the tumor without disrupting
the dermis so that scarring is less likely. NsPEF Tx should also be effective on other
tumor types located deeper in the body if a catheter electrode can be guided to the tumor.
Besides surgical removal, other treatment options for metastatic lesions vary
according to malignancy, nature and stage of the tumor. Melanoma has a high resistance
to cytotoxic agents. Only two chemical medicines are approved by United States Food
and Drug Administration (FDA) for use in patients with metastatic melanoma:
dacarbazine and IL-2. Both agents have an overall response rate well below 20%, with
long-term response uncertain.5
Dacarbazine was approved by FDA 25 years ago and is now the only FDA-approved
single-agent chemotherapy for metastatic melanoma. Dacarbazine is an alkylating agent
with no benefit in terms of relapse or survival.6 Dacarbazine also has high toxicity to all
rapidly dividing cells in addition to tumor cells. For example (1) Blood cells: These cells
are vital because they fight infection, help the blood to clot, and carry oxygen. When
chemotherapy affects blood cells, patients are more likely to get infections. (2) Cells in
The journal model for this dissertation is International Journal of Cancer.
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hair follicles: Chemotherapy can lead to hair loss. (3) Digestive tract: Chemotherapy can
cause poor appetite, diarrhea nausea and vomiting. Patients need to take other drugs for
these side effects. Even with these serious side effects, no substantially superior single
agent has yet been found a replacement.7
Among other therapeutic strategies studied in metastatic melanoma, immunological
approaches have yielded the only new FDA-approved agent for metastatic disease, highdose (HD) bolus interleukin 2 (IL-2).8 IL-2 was the first immune cytokine to be
molecularly characterized as a lymphocytic growth factor. EL-2 is a pleiotropic
glycoprotein which is essential in the activation of a specific response to antigens by T
cells, but also in triggering the innate immunity by stimulating several functions of NK
cells and macrophages. However, like dacarbazine, IL-2 therapy causes high toxicity
such as accumulation of fluid, flu-like symptoms, confusion, weight gain, low blood
pressure and irregular heartbeat.9
Why are melanoma tumors areso resistant to chemical therapy? Some researchers10
believe that cell hierarchy resides inside melanoma tumors and only a few chemotherapyresistant cancer stem cells generate the new tumors. Most current therapies target the
non-cancer stem cells which makes up the bulk of the melanoma but the resistant stem
cells can always escape and survive allowing the tumor to recur after therapy seems
effectively progressing. Only those therapies that specifically target the cancer stem cells
can completely eradicate melanoma tumors. Studies of cancer stem cell are now focusing
on gene-expression patterns which will differentiate them from normal melanoma cells.
Melanoma has traditionally been approached either systemically with chemotherapy,
or locally with surgery or radiotherapy. Researchers have recognized the lack of
effective therapies and are looking for improve treatments. More physically oriented
methods have emerged in cases when surgery is impossible or contraindicated due to
high risk. The physical methods accepted in clinical practice as non-surgical methods
are minimally-invasive therapies such as localized radiotherapy,11 Laser ablation 12 and
radiofrequency ablation.13
The localized radiotherapy-carbon ion beam, which is a high linear energy transfer
(LET) beam, has unique physical and biological properties. The range is well-defined
and has insignificant scattering which allows focused penetration that can go into tissues.
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This energy deposition is localized and can cause oxygenation-independent cell damage.
However LET has not yet been fully validated by long-term survival statistics for the
adverse effect of the radiation itself.13
Laser ablation has the advantage of being rapid and painless. Delivery of the beam
however is so invasive that it should be contraindicated except in last ditch efforts. For
accurate location, laser ablation often needs to be guided by magnetic resonance. To
achieve successful tumor treatment, wide tissue margins around the tumor have to be
coagulated which produce necrotic tissue, increasing the risk to vital organs around the
tumor.
Radiofrequency ablation (RFA) is a thermal therapy along the order of microwave,
laser, high-intensity focused ultrasound, and cryotherapy which use temperature change
to kill tumor cells. RFA can raise tumor temperature to lethal levels for tumor cells.
Recent developments in radiofrequency ablation technology make large-volume tissue
ablation possible for melanoma as an attractive option for patients unable or unwilling to
accept surgery. RFA provides safe and effective local treatment of melanomas. The
energy causes ionic agitation producing frictional heat, which cooks the tumor and leads
to cell death and necrosis. The time for the body to gradually replace the necrosis by
fibrosis can be quite lengthy.
One treatment that combines both physical and chemical therapy that has caught
people's attention is electrochemotherapy.14 Electrochemotherapy is a creative
combination that uses chemotherapy followed by local application of electric pulses to
the tumor. Electric fields have been proven to increase drug delivery into the cells, which
combines the physical effect of cell membrane poration with die chemotherapy drug
dose.15
Electrochemotherapy is special because it uses a pulsed electric filed to alter the
tumor cell membrane.16 Electrochemotherapy requires a generator and electrodes. The
generator produces the electrical pulse while the electrodes deliver the pulse into the solid
tumor.17 The general parameter requires hundreds of volts/cm at microseconds
duration.18 These temporary pores originate from the pulsed electric field thus increasing
cell membrane permeability which enhanced the chemotherapeutic drugs uptake which
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would naturally have a poor permeability without electroporation. When the application
of the electric field stops, the temporarily-formed pores immediately close.19
In electrochemotherapy, the pulsed electric field is used as a local drug delivery
approach.

Bioelectric researchers are more interested in using the pulsed electric field

alone. They want to develop a chemical free, non-ionizing, non-thermal physical therapy
that could trigger apoptosis by a different mechanism or pathway.21 The recent
development of nsPEF produces unique characteristics that may solve the problems
caused by heat. NsPEF Tx initialize high electric fields (kV/cm) applied with ultra short
durations (nanosecond). Quite different from classical plasma membrane electroporation,
nsPEF can produce highly compressed power (billions of watts), ultra short pulse
durations (nanosecond), rapid rise times (nanosecond), and high electric fields (kV/cm).
The resulting nanosecond pulse is so short that it can penetrate into the cell before the
plasma membrane is fully charged allowing nsPEF to have minimal affect the plasma
membrane therefore not causing electroporation.
nsPEF has had military applications,its application in biology creates a new academic
subject: Bioelectrics, which means applications of ultra-short pulsed electric fields to
biological living cells, tissues, and even organs. This new burgeoning branch of research
analyzes how biological systems react to high electric fields applied with very short pulse
nanosecond duration. NsPEF Tx has been applied in fighting against bacteria and has
demonstrated decontamination potential. Only in recent years has it been applied to
mammalian cells following careful modeling research and studies using non-mammalian
cultured cells.21 The main characteristics of nanosecond pulsed electric fields are their
high power and low energy leading to very little heat production and their special ability
to penetrate into the cell to penetrate intracellular organelles.

NsPEF Tx is unique

because of its non-electroporation effect on the plasma membrane.24
During the past years a number of studies have been done to determine biological
effects of nsPEF Tx in cultured cells. The results proved that nanosecond pulse
stimulation of a variety of cells produces a wide range of physiological responses. In
vitro studies on cells treated by nsPEF include: (1) p53-wild type and p53-null HCT116
(human colon carcinoma); (2) HL-60 (human promyelocyte leukemia); (3) Jurkat
(human peripheral blood, leukemia);27 (4) B16F10 (murine melanoma);28 and from a
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paper by Stacy, et al.,

(5) BS-LCL (human B-cell lymphoblastoid line from a patient

with bloom syndrome); (6) AT-LCL (Human B-cell lymphoblastoid line from a patient
with ataxia-telangiectasia); (7) SV-Normal (Human SV40 transformed normal
fibroblasts); (8) SV-AT (human SV40 transformed fibroblasts from a patient with ataxiatelangiectasia); (9) SV-FA (human SV40 transformed fibroblasts from a patient with
Fanconi's anemia); (10) SV-XP (human SV40 transformed fibroblasts from a patient with
xeroderma pigmentosum); (11) HS578T (BrCa-human ductal breast carcinoma); (12)
HeLa (human adenocarcinoma of the cervix); and (13) 3T3(mouse pre-adipocytes).
Effects of nsPEFs on cells in vitro include: (1) apparent direct electric field effects; (2)
induced apoptosis leading to caspase activation and then cell death; (3) nuclear changes
and modified cellular functions with delayed plasma membrane effects becoming smaller
as the pulse duration is shortened; (4) release of calcium from internal calcium pools and
activation of plasma membrane calcium influx channels or capacitative calcium entry
(like ligand-mediated responses); (5) induction of DNA and cell cycle anomalies; and (6)
diminished cell survival. The biological effect of nsPEF Tx on cells in vitro is directly
related to the electric filed strength, the pulse number and the pulse duration.
The effect of nsPEF Tx on multicellular tissue or human subjects has not been tested
until very recently. An ex vivo study on mouse embryonic fibroblasts was the initial
approach for testing nsPEF effects on tissues. Fibrosarcoma tumors (B10.2) were
injected in the flanks of C57B1/6 mice and then excised and exposed to nsPEF Tx.
or*

Fibrosarcoma B10.2 cells ex vivo became reduced in size after nsPEF Tx. Because the
tumors were removed from the animals before Tx then sliced and exposed to nsPEF Tx in
cuvettes, the experiment was ex vivo rather than in vivo. Therefore the data cannot
substituted for an in vivo experiment.
Based on the previous in vivo and ex vivo work, nsPEF Tx is hypothesized as a highly
localized, drug-free, non-thermal physical technique which would be a new therapy for
tumor treatment. To apply nsPEF Tx to tumors in vivo is an important bridge to connect
individual in vitro cellular response with future clinical application. This emerging field
has unknowns surrounding the nsPEF mechanism of actions on the in vivo tumors. Our
study provides prospective research data on nsPEF Tx on solid in vivo tumors.

6

Proof of apoptosis induction and anti-angiogenesis sheds light on the mechanism of how
nsPEFs work on tumors. Since nsPEFs act as a non-chemical, non-thermal and nonligand pulse that did not exist in the natural environment, these studies reveal new
understandings of apoptotic and angiogenic signaling pathways in tumor tissues.
While a number of studies have been done to determine effects and mechanisms of
nsPEFs in cultured cells, much remains to be done to determine nsPEFs effects on tumor
tissues in vivo.
A previous in vivo case study was reported for a single patient. A nsPEF Tx was
applied (150 pulses of 20 ns duration, and 60kV/cm) to both normal and malignant cells
such as WI-38, a cell line established from normal human fetal lung fibroblasts, and VA13, the matched WI-38 cells transformed with the SV40 virus (which inactivate sp53 and
Rb). Cell viability after pulsation didn't show an immediate response which made them
believe the final cell death or slowed cell proliferation were delayed results instead of the
immediate response of cell membrane destruction. When nanoelectropulse therapy was
applied to AsPC-1 tumors in athymic nude mice, a response was seen in 4, the effective
rate was 66.7% and the biological effects included clinically complete remission in 3 of 6
animals. A single male human had nanoelectropulse therapy with 200 pulses (10 pulse
bursts every 5 sec, 6.5 kV, 20 ns duration, 20 Hz) applied to a basal cell carcinoma with
complete elimination. These trials show interesting therapeutic effects but were limited
by the sparse case numbers without repetition or controls and thus without statistics.28
Our current project is designed to determine tumor response and molecular
mechanisms for melanoma regression with nsPEF Tx in vivo. More specifically SKH-1
female mice bearing B16-F10 murine melanomas have been treated with 100 pulses of
nsPEF Tx at 300 nanosecond pulse duration, 40 kV/cm electrical density at 0.5 Hz rate.
Tumor growth inhibition was observed, the number of survival days was tracked after the
nsPEF Tx and the biological effects such as induction of apoptosis and anti-angiogenesis.
The mechanism of nsPEF parameters to affect biological results was also studied. This
research is a unique prospective animal trial for nsPEF application in vivo. Our data,
drawn from a large experimental animal population (more than two hundred), tested the
pulse effects over three different time frames: (1) short-term observations (minutes after
nsPEF Tx); (2) intermediate observation (days after nsPEF); and (3) long-term
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observation (5-month survival study). In vivo data were provided that is impossible to
gather with in vitro cell cultures like vascular changes and tumor regression over a realtime framework. Following nsPEF Tx, the kinetics of tumor regression was determined
by using ultrasound analysis of tumor volumes and inhibition of tumor blood flow by
Doppler ultrasound. This study not only recorded the tumor response but has also
revealed possible mechanisms of actions. Molecular events were also determined to be
triggered by nsPEF Tx.
The 5 chapters in the dissertation will test the following specific aims:
1. To analyze the tumor volume quantatively after the nsPEF Tx to study if nsPEFs can
cause tumor growth inhibition and ultra structural changes.
2. To determine if nsPEFs can (1) damage nuclei or DNA as measured by H2AX
phosphorylation and TUNEL or (2) affect the related proteins such as caspase, 6, 7, bcl-2,
BAD expression by immunohistology and western blot, thus allowing the kinetics of
molecular events related to apoptosis post-nsPEF Tx to be determined.
3. To compare the tumor blood vessel changes, micro-vessel density and the
angiogenesis related proteins such as vascular endothelial growth factor (VEGF), and
platelet-derived endothelial cell growth factor (PD-ECGF) expression in the tumors with
and without nsPEF Tx.
4. To study long-term animal survival rate after nsPEF Tx in mouse-survival days and
tumor growth and recurrence in the primary site.
5. To determine the relationship between the in vivo biological effect as related to the
nsPEF Tx dose.
Our results produce evidence that nsPEF Tx is an emerging modality that may have a
role as a local cancer therapy. Therefore the data will form the basis for future human
clinical applications in tumor therapy.
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CHAPTER II
NSPEF INHIBIT MELANOMA GROWTH AND PRODUCE
ABNORMAL TUMOR MORPHOLOGY
According to epidemic data from American Cancer Society, there are 53,600 newly
diagnosed melanoma cases and 7,400 deaths per year, a 15-fold increase over the past
four decades in the United States.31 Treatment options for advanced metastatic
melanoma are limited and the clinical prognosis is poor.32 The only single agent therapy
approved by the FDA is a chemotherapeutic medicine, decarbonizes (DTIC). It has
severe side effects and brings no apparent survival benefit.33 The challenges of therapy
require new methods. Pulsed power technology has attracted attention for its unique
biological effects on tumor growth. The application of high power and low energy makes
nanosecond pulses pass the cells exterior plasma membrane but shocks the vital
intracellular structures.34 More recently, it has been shown in silico that unique nanopores
are formed in all cell membranes including the plasma membrane.
nanosecond pulsed electric field (nsPEF) is a high electric field applied with ultra
short pulse duration35 (20kV/cm at 300 nanosecond in our research). Compressed power
is extremely high (billions of watts) while the duration of nanosecond pulses are
extremely short thus producing very low energy density with no thermal consequence in
living cells.36
Prior in vitro research in our center has proven that pulses with high-intensity electric
fields can affect intracellular structures producing a wide range of physiological
responses (e.g., apoptosis, stimulation of calcium (Ca2+) fluxes, changes in membrane
potential) in different cell lines such as HL-60 (Human promyelocytic leukemia cells),37
Jurkat (human T cell leukemia cells)38 and HCT116 (colon carcinoma cells)39. But the in
vivo proof is still absent.
In the present work, an animal model was set up and investigated the direct tumor
response of nsPEF on tumor growth, and examined the morphological characteristics of
nsPEF in the treatment of subcutaneous murine melanoma B16F10.
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Material and Methods
B16F10 cells
Murine melanoma B16-F10 cells were obtained from ATCC (Manassas, VA) and
cultured in DMEM (Dulbecco's modified Eagle's medium) supplemented with 10% fetal
bovine serum (FBS, Atlanta Biologicals), 4 mM 1-Glutamine (Cellgro), and 2%
Penicillin-Streptomycin solution (Cellgro) at 37°C in 5% C02.
Animals
In vivo experiments were set up in conformity with IACUC guidelines under
applicable international laws and policies (Animal Care and Use Committee of Eastern
Virginia Medical School IACUC #04-011, #04-013). B16 F10 cells were implanted
subcutaneously in the right and left flank of the SKH-1 female mice using 0.1 ml of cell
suspension with l x l 0 6 B 1 6 F 1 0 cells prepared from in vitro cell cultures. Three tumors
per mouse were induced; the treated tumor had electrode placement and nsPEF Tx. The
sham tumor had electrode placement only without nsPEF Tx. The control tumor had no
electrode placement or nsPEF Tx.
In vivo imaging
Before and after the treatment, melanomas were imaged daily by both
transillumination and surface photography at 1.2x magnification. Tumor volume was
calculated. Tumors were measured daily after the treatment using the formula 40 for
prolate spheroid (square of the width x length x 0.52): V = 0.52 x Dl 2 x D2, where Dl
and D2 are short and long tumor diameters, respectively in vivo using tranillumination
and surface photography.
NsPEF Tx
Pulses were generated using 40 KV/cm, 300 nanosecond pulses with a rise time of
about 30 nanoseconds by a Blumlein pulse generator designed and assembled at the
Frank Reidy Research Center for Bioelctrics. Three tumors induced on the same mouse
were randomly selected as control, sham or treated tumor. An area of skin was pulsed in
the same way as the treated tumor for safety evaluation and a second area of normal skin
was collected without pulse or electrode placement as a skin control. One hundred pulses
were applied to the treated tumor and treated skin at a frequency of 0.5 Hz with a needle
electrode.
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Histology study
Upon euthanasia, tumors were removed and fixed in 10% neutral buffered formalin
prior to paraffin processing. Sections were stained with H&E and assessed
microscopically for abnormal cell morphology. One hundred nuclei were randomly
selected and outlined in ten non-overlapping fields of each section at 600x magnification.
The nuclear area was calculated by MATLAB software and summed as the mean ± SD
for statistical analysis. Fontana-Masson stain and Iron stain (hemosiderin) followed a
routine protocol described.41'42
Transmission electron microscopy
After pulsing, the treated and the control tumors, along with the normal skin samples
were excised and immediately put into primary fixation (3% glutaraldehyde) for two
hours at room temperature and then secondary fixation (1% osmium tetroxide) was
carried out in the dark at room temperature for one hour followed by repeated washing
(3x) with phosphate buffer. Dehydration was accomplished with a series of 30%, 50%,
90% and 100% ethanol (v/v) for 15 min each. The dehydrated samples were suspended
in propylene oxide followed by 1:1 treatment with propylene oxide: resin and finally with
pure resin until infiltrated by resin polymerized. The resin blocks were carefully trimmed
and various thicknesses (200nm, 300nm, and 500nm) were cut using an ultra microtome.
Tissue ribbons were transferred to 300 mesh copper grids stained with uranyl acetate and
lead citrate and then analyzed with a Jeol electron microscope at 160 kV.
Result
Tumor growth was inhibited by nsPEF Tx: Histological analysis.
A self-comparison model was set up to avoid the heterogeneity derived from
differences mice. Three melanomas were induced on every SKH-1 mouse and decided
randomly to be used as control, sham or treated tumor. The pulsed skin around the tumor
was also collected to compare with the normal skin for further nsPEF safety evaluation.
Altogether 12 mice were included in the 7-day-long tumor growth observation.
Histological data showed that 100% of the treated tumors (12/12) responded to the nsPEF
Tx compared to the sham and control tumors. The major pathological diagnosis was
summarized as Table 1.
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I - OVERVIEW OF H&E AND TEM MORPHOLOGICAL CHANGES
SUMMARIZED FROM 120 MICE BEARING MELANOMAS WITH OR WITHOUT
NSPEF T x
TABLE

Nucleoli

Control tumor
Regular nest and cancer cell cord
Lobular
Rich
Complete
Clearly and evenly spread throughout
nucleus
Structured with organelles
less pleomorphic with relatively regular
contour,
regular and well formed

Melanin

most located inside the cell

Tumor structure
Tumor Center
Blood supply
Tumor nest
Nuclear chromatin
Cytoplasm
Nuclei

Treated tumor
disordered
dead
poor
destroyed
aggregated
cytoplasmic details lost
more heterochromatin,
condensed, elongated and dark
more pleomorphic, compact,
prominent, and irregular in shape
Some within cytoplasm but much
scattered extra cellular space

Tumor growth was inhibited with nsPEF compared to the control tumors from the same
mouse.
To avoid the individual tumor growth difference due to the immune system, tumors
injected on the same mouse were randomly selected as the treated tumors (n=12)
compared with controls (n=12) and shams (n=12). One week after nsPEF Tx the volume
of tumor size showed significant difference (p<0.00l). Control tumors on 12 mice grow
faster and larger than the treated tumors on the other side. The skin in the tumor area was
also pulsed. Edema and bleeding appear after nsPEF Tx and lasted 3 days. The skin
damage underwent a week long recovery and eventually healed.
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FIGURE 1 - Tumor growth was inhibited 7 days post-nsPEF Tx compared with control tumors from the same
mouse. H&E comparison of the melanomas with or without nsPEF from the same mouse. For every mouse
two tumors were injected on the same mouse but selected randomly one for nsPEF Tx and the other without
any treatment used as a self-control. A and E, B and F, C and G, D and H are the tumors grown up on the
same mouse (40x). Four different control tumors are shown in the top row; four treated tumors are shown
in the middle and the skin in the nsPEF treated tumor areas were shown in the bottom row. I: pre-pulse
skin (200x). J-K: post-pulse skin. J: First day post nsPEF Tx (200x). K: Third day post nsPEF Tx (200x). L:
Seventh day post nsPEF Tx (40x).

Typical growth change after nsPEF Tx recorded by transillumination and surface
photography

Pulsed skin undergoes an acute edema, with local bleeding 10 minutes and 2 days
post treatment. On day 2 a shallow scar was observable on the surface, which recovered
by day 7. Control tumors size increased continuously on days 2 and 7 maintaining a rich
blood supply. Treated tumor growth was inhibited and a surface scar developed and
tumor blood vessels disappeared as the tumors shrunk.
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FIGURE 2 - Typical growth change after nsPEF Tx recorded by transillumination and surface photography.
The images (1.2 x magnifications) show pulsed skin (top row) untreated control tumors (middle row) and
tumors treated with nsPEFs with 100 pulses at 300ns and 40kV/cm (bottom row). Images were taken 10
minutes, 2 days and 7 days post nsPEF Tx as indicated. Images were taken of the surface and with
transillumination as illustrated.

Tumor volume changes during 7-day post-nsPEFs treatment
Tumor volume changes during the first week post nsPEF Tx were plotted (Fig.3).
Local treatment with nsPEF decreased the tumor volume significantly compared to the
self control tumors. The sham was made by putting the electrode on the tumor without
delivering the electric field. The sham tumor volume and growth curve had no significant
difference from the control tumor, which indication that electrode insertion didn't
account for the tumor reduction.

Tumor growth curve

Time after nsPEFs treatment (day)

FIGURE 3 - Tumor volume changes during 7-day post nsPEFs treatment. Tumor volume was determined
using calipers on days 1, 3 and 7 after treatment with 100 pulses at 300ns and 40kV/cm. Tumor volume for
treated (n=12) was compared with controls (n=12) and sham (n=12), calculated and shown as cm3 as
described in Materials and Methods. (* p <0.001)
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Inferior view of tumors collected pos- euthanasia.
When the mice were euthanize, all tumors (n=36) were removed and photographed from the
epidermal and subcutaneous surfaces. Figure.4 showed the inferior view of tumors. Twelve
tumors from control group were large in size and rich in blood supply. The sham was similar to
the control group. Twelve tumors from nsPEF treated group showed that tumor size decreased
dramatically without an obvious blood supply around the tumors.

FIGURE 4 -

Inferior view of tumors collected post euthanasia. Tumors were removed from the mice after
euthanasia. All tumors (n=36, 12 per group) were removed and photographed from the epidermal and
subcutaneous surfaces. Tumors were dissected then weighted for statistical analysis. Thefirstframe shows
12 tumors from control group as indicated. The second frame shows 12 tumors from sham group and the
third frame shows 12 tumors from nsPEF treated group.
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Tumor weights was decreased 14 days post nsPEF treatment compared to the control
and sham from the same mouse
Figure 5 showed nsPEF treated tumor volume was inhibited 14.8% of control tumors
(p<0. 001). No differences were observed between control and sham tumors

Tumor weight comparison

i

*

rh
control

sham

treated

5 - Tumor weights was decreased by nsPEF treatment compared to the control and sham from the
same mouse. Tumors were removed from control, sham and treated mice and weighed 14 days post nsPEF
treatment (100 pulses, 300ns at 40kV/cm)
FIGURE

Melanoma tumor cell structure and nucleus were changed by nsPEF treatment.
Ultra structure and nuclear change were revealed by H&E. Control tumors showed
the aggressive growth, regular nest shape with rich blood supply. The solid tumor was
bounded by a thin fibrous capsule and contained internal fibrous bands, demarcating
multinodular characteristics. Nests of tumor cells were delineated by well-formed basal
lamina, composed of cellular lobules separated by hypocellular, fibrous bands. Nested
patterns of growth were identified within these lobules. Tumor cells featured clear and
regular nuclei with prominent nucleoli. The cytoplasm is characteristically pink and
clear. Pigment suggestive of melanin was identified in an organized shape. Treated
tumor nuclei dramatically shrink. Nests break down, losing the cord-like supporting
structure on which tumor cells extend. Individual cells elongated and condensed, nuclear
to plasma ratio decreased. Dense cytoplasmic bodies make the field dark, unclear and
disordered. The arrows point to the tumor nest in the low magnification and the typical
tumor cells and melanin in high magnification.
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FIGURE 6 - Melanoma tumor cell

structure and nucleus were changed by nsPEF treatment. Melanoma cell
structure and nuclear changes were analyzed by H&E. Control tumors are stained by H&E and then
photographed under 40x and 600x magnification. The arrows point to the tumor nest in low magnification
and the typical tumor cells and melanin in high magnification. Bar scale: 2cm on the top line and 50 micro
meters on the bottom line.

Melanoma tumors nuclear area was decreased by post nsPEF Tx.
Nuclear area changes of melanoma tumors post nsPEF treatment was shown in
Figure.6. Control tumors (n=12) and nsPEF treated tumors (n=12) were compared by
their nuclear area. A significantly decreased nuclear area was seen in tumors as indicated
7 days after nsPEF treatment, (p < 0.05)
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7 - Melanoma tumors nuclear area was decreased by post nsPEF Tx. Specimens were collected
when mice were euthanized on the 7* day post nsPEF treatment. Control tumors (n=12) and nsPEF treated
tumors (n=12) were routinely stained with H&E and analyzed by a computer-assisted image analysis with
MATLAB as previously described. The nuclear area decreased significantly after nsPEF treatment (* p <
0.05)
FIGURE

Melanoma tumor cell sub-cellular structures was changed by nsPEF Tx
Sub-cellular structures were analyzed by transmission electron microscopy (TEM).
Full-thickness biopsy was made from normal skin, control and nsPEF treated tumor.
TEM showed the untreated skin has the typical sub-cellular organelle. The control tumor
revealed typical malignant melanoma morphology: regular shaped nucleus with high
proliferation and prominent nucleoli in the center, extensive rough endoplasmic
reticulum, Golgi stacks, and a large quantity of ribosomes. In contrast, the nsPEF treated
melanoma showed: (1) decreased nuclear size but increased nuclear /cytoplasmic ratio,
(2) formation of dense cytoplasmic bodies, (3) degenerative tumor cells with
fragmentation of nuclei and irregular nuclear outline.
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Normal skin

Control tumor

nsPEF treated tumor

FIGURE 8 - Melanoma tumor cell sub-cellular structures was changed by nsPEF Tx. Melanoma tumor sub
cell structure was analyzed by Transmission Electron Microscopy (TEM). Full-thickness biopsy of normal
skin, control and nsPEF treated tumor from the same mouse 7 days post nsPEF Tx were dissected as shown
in the upper row. The corresponding TEM was shown in the lower row. The first TEM picture on the left
shows the mouse skin has the typical epidemic sub-cellular organelle. The arrow points to the nucleolus
inside the normal epithelial cell. The TEM picture in the middle shows a control tumor. The arrow points to
the nucleolus inside B16F10 cancer cell. The TEM picture on the right shows a treated tumor (100 pulses
at 300ns and 40kV/cm). The arrow points to the fragmentation along the cell membrane inside a
condensed, shrunken and wrinkled B16F10 tumor cell

Fontana stains for melanin in the melanoma tumors 7 days post nsPEF Tx.
Fontana stain for melanin was shown in Fig.9. Dark spots reveal the melanin layers
which were clearly represented with Fontana Stain, a positive, marker for melanin.
Control tumors without nsPEF treatment showed a layer of positive Fontana stain which
outlines of malignant melanoma. Tumors post nsPEF treatment showed decreased
volume with sparse melanin remaining. The staining results suggest nsPEF treatment can
reduce or eliminate the melanin in the tumor. Based on the control tumor as a
comparison, this staining change is an indirect sign of tumor damage. In tumors where
the melanin persist post-nsPEF treatment, the melanin will be aggregated in extra cellular
spaces and not within cells which indicates the cell death.
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Fontana
Melanoma
Positive control without nsPEF

Melanoma
with nsPEF

Normal skin

FIGURE 9 - Fontana

stain for melanin in the melanoma tumors 7 days post nsPEF T,. The first column (A,
E, I, Fonata positive control) shows the human melanomas without treatment. The second column (B, F, J,
melanoma without nsPEF) shows the mouse control tumors without nsPEF treatment. The third column
(C, J, K, melanomas with nsPEF) shows tumors post nsPEF treatment. The fourth column (D, H, L, normal
SKH-1 normal mouse skin) show negative Fontana stain because the SKH-1 mice are albino and thus
almost no melanin in the skin. The arrows point to the melanin layer.

Iron stain for the old bleeding in the melanoma tumors with and without nsPEF Tx.
Iron stain of the mouse melanomas was shown in Fig. 10. This extracellular
hemoglobin/iron combines the iron stain. Control tumors showed melanin, but no iron.
Treated tumor had positive iron staining. The micrographs indicate nsPEF causes some
capillaries damage with hemoglobin of red blood cells accumulation within the treated
area.
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Melanoma
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10 - Iron stain for the old bleeding in the melanoma tumors with and without nsPEF Tx. A, E and I
(Iron stain positive control) show iron in granules in human melanoma. B, F and J (melanoma without
nsPEF) show tumors with melanin, but no iron. C, G and K (melanoma with nsPEF) show layers of
positive iron staining. D, H and L are normal mouse skin as the iron stain negative control. The arrows
point to the cells which indicate iron stain positive
FIGURE

Discussion
Electric fields applied to living cells cause a number of significant biological
effects.43 The most common application of pulsed electric fields is classical plasma
membrane electroporation by which foreign drugs can be introduced into cells through
temporary formation of pores in the plasma membrane.44 Electroporation pulses charge
the plasma membrane with millisecond to microsecond durations and low electric fields
(V/cm to KV/cm), without significant effects on intracellular membranes. Quite different
from classical plasma membrane electroporation, nsPEF is special for its ultra short
nanosecond pulse duration, rapid nanosecond rise time, and high electric field (kV/cm).
As a result, nsPEF can generate ultra short pulses, which are short enough to penetrate
the cell interior before the plasma membrane is fully charged.45 nsPEF Tx can bypass the
plasma membrane because the cell membrane has a relaxation time longer than the pulse
duration. Pulses of nanosecond duration in our previous trials showed 100 pulses
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increase the temperature of the treated region by only 3 degrees C, ten degrees lower than
the minimum temperature for hyperthermia effects.46 NsPEF Tx shows high power and
low energy leading to very little heat production. The consequence of applying intense
300 ns pulses was examined on melanoma bearing mice. This study analyzes melanoma
growth and ultra structure post nsPEF treatment. The hypothesis that nsPEF is a highly
localized and drug-free physical technique was confirmed. NsPEF could serve as a
promising new therapy for tumor.
After nsPEF treatment, the tumor showed delayed development and sharply
decreased volume on the first, second and third day compared to control tumors (p<0.05).
The nsPEF-treated tumor weight was reduced by 85.3%, significantly smaller than the
control group (p<0.00l).
Transillumination and surface photography showed a consistent change after nsPEF
treatment while the untreated melanomas were grossly recognizable under the skin
surface with round black enlarged appearance on the back. The treated tumors were
small and dry with structural shape change and reduction of blood vessel.
H&E and TEM images both showed that without nsPEF treatment, the melanomas
kept a regular outline of tumor cells with a pale nucleus and prominent round nucleolus.
Cell cytoplasm was finely dusted with melanin and the cells often formed a tumor nest
with an active growing center marked by a good blood supply and a well-organized
cancer cell cord marked by invading vessels, dermis or muscle fibers. Lymphatic and
vascular invasion was present in some control samples, but not as prominent as in the
treated group. In nsPEF treated melanomas, solid tumor nest construction was detached,
tumor cords were broken and the space in between tumor cells enlarged with shrinking
spindle shaped nuclei inside. Regression in size of tumors occurred within 24 hours with
surrounding tissue swelling and bleeding. Subcutaneous tissue and skin recovered within
7 days. Skin pulsed with nsPEF showed evidence of typical inflammation in the treated
area during the first three days but resolved in one week. Summarizations of pathological
comparisons are formed in Table 1.
Fontana-Masson stain was used to assess depigmentation of melanomas after nsPEF
treatment. Because melanomas develop from the malignant transformation of
melanocytes, specialized melanin producing cells which reside in the epidermal basement
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membrane of the skin, melanogenesis is regarded as a functional marker associated with
differentiated melanocytes. The data shows the effects of nsPEF on organized
melanogenesis and retention of intracellular melanins.
Iron staining can show hemosiderin which is the storage molecule for iron granules
so that iron staining can mark recent bleeding by staining the hemoglobin iron released
by lysed red blood cells. The data showed iron stain in the treated melanomas, a sign of
hemorrhage indicating that nsPEF caused acute blood vessel rupture and bleeding inside
the tumor
Melanoma morphological changes revealed that nsPEF can inhibit melanoma growth
in vivo. NsPEF can significantly delay subcutaneous murine melanoma development by
directly damaging the tumor structure and nuclear morphology without significantly
affecting the peripheral healthy skin tissue of the treated mice.
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CHAPTER III
NSPEF TRIGGER APOPTOSIS IN MELANOMA IN VIVO
Previous studies from this laboratory demonstrated that nsPEF could eliminate
B16f 10 tumors in mice. Our former studies47 on the first 120 mice with nsPEF Tx show
that nsPEF can penetrate into the interior of melanoma cells and cause tumor cell nuclei
to rapidly shrink and reduce tumor growth with gradual remission in weeks.48 Different
mechanisms and pathways have been found in the initial apoptosis detection in tumor
cells in vitro.49'50 The hypothesis is that nsPEF Tx triggers apoptosis in tumor in vivo.
Apoptosis differs from necrosis because it is an active process of cellular self-destruction,
involves a precisely controlled series of events that become activated in a cell signally its
time to die. The current work is designed to find out sequence of molecular events
caused by nsPEF in the short term (1-24 hours) post-nsPEF Tx.
Twenty four SKH-1 mice bearing B16-F10 murine melanomas were euthanized at
1, 3, 6 to 24 hours post-nsPEF Tx. The objectives were: to (1) survey the melanoma
nuclear morphological changes (2) examine the presence of DNA damage, caspase
activation and apoptosis; (3) determine time sequence of the molecular biological events.
(4) compare the different biological effects of long pulses versus short pulses.
Material and Methods
Tumor Model
In vivo experiments were set up in conformity with IACUC guidelines under
applicable international laws and policies and approved by Animal Care and Use
Committee of Eastern Virginia Medical School. In accordance with principles for the
ethical use of animals, 24 immunocompetent hairless female SKH-1 mice were injected
subcutaneously with 100 ul PBS containing lxl0 6 B16-F10 murine melanoma cells.
nsPEF Tx
A pulser with a Blumlein line configuration was designed and assembled at the
Frank Reidy Research Center for Bioelectrics. It can generate 300 nanosecond long
pulses with a 30-nanosecond rise time. One hundred pulses were applied to the treated
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tumor at 40 Kv/cm and 0.5 Hz. The electrodes for electric field application, pulse
generator, voltage and pulsing pattern of nsPEF were described previously.48
Sample collection
Specimens were collected for 4 different time points post-nsPEFs Tx (1, 3, 6 and 24
hours). At each time point, 2 groups (nsPEF-treated tumors and the control tumors on the
same mouse) consist 6 replicates per group, were studied.
Histology Study
Two tumors induced simultaneously on the back of each mouse were randomly
selected as either control or treated tumor. After the nsPEF Tx both control and treated
tumor were removed and fixed in 10% neutral buffered formalin prior to paraffin
processing. Sections were stained with H&E and assessed microscopically for abnormal
nuclear formation. One hundred nuclei were randomly selected and outlined in ten nonoverlapping fields of each section.51 The area of nuclei was measured by the software
MATLAB and summed as the mean+SD for statistic analysis.
DNA fragmentation
DNA was extracted by standard proteinase K and phenol/chloroform.
Electrophoresis was performed in 1.8% agarose gel in TBE buffer (Tris-borate 89 mM,
pH 8.3, EDTA 2 mM) at 30 V for lh. The DNA was visualized by ethidium bromide
staining. B16-F10 cells incubated with Etoposide (Calbiochem, Cat. 341205) used as
apoptosis positive control.52
Immunofluorescent Staining
Mouse tumor sections were de-paraffinized and then immerged into and boiled in
citrate buffer (pH 6.0) for 5 minutes to retrieve antigenic sites masked by formalin
fixation. The tissue sections were then placed in 3% hydrogen peroxide for 10 minutes to
inactivate endogenous peroxidase. Tissues were blocked with goat serum, and then
incubated in a humidity tray with antibodies against phospho-histone H2AX (SI39) (RD;
1:500 dilution); caspase 3 (Cell Signaling, 1:500), caspase 6 (Cell Signaling, 1:800),
caspase 7 (Biovision, 1:400) in combination for 2h at room temperature. This was
followed by incubation of a secondary antibody, Alexa Fluor-488-labeled goat anti-rabbit
IgG (Invitrogen, 1:250) for 30 min at room temperature in darkness. Cover slips were
mounted with mounting media (Vector Laboratories, H-1200), which contained DAPI to
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identify the nuclei. The number of positive cells was scored by manual counting of three
sets of at least 100 cells under the microscope. Each experiment was performed twice.
TUNEL Assay
TUNEL (terminal transferase mediated ddUTP nick end labeling) assay was done
according to the protocol with Apot Tag Red in Situ, an apoptosis detection kit,
(Chemicon, Cat No. S7165). Cells with TUNEL-positive nuclei with a cytoplasmic halo
were recognized as positive apoptotic cells. For the negative control, no terminal
transferase enzyme was added.
Western Blot Analysis
Proteins were resolved over a 15% SDS-polyacrylamide gel and transferred to a
nitrocellulose membrane. Gels were transferred electrophoretically to a polyvinylidene
difluoride (PVDF) membrane. The blot was preincubated in blocking buffer (5% nonfat
dry milk, 1% Tween 20, in 20 mM TBS pH 8.0) for 1 h at room temperature, then
incubated with appropriate primary antibodies in blocking buffer for 1 h at room
temperature, overnight at 4°C followed by incubation with anti-rabbit or anti-mouse
secondary antibodies conjugated with horseradish peroxidase and detected by
chemiluminescence and autoradiography using x-ray film. The antibodies against Bcl-2,
Bad, beta-actin and caspase-9 demonstrated several bands with the most intense staining
at the predicted molecular weight in each case. The antibodies were abtained as following
: Bcl-2: (Santa Cruz Biotechnology Inc. Catalog #: sc-23960, dilution: 1:200, molecular
weight: 26 kDa,); Bad: (Santa Cruz Biotechnology Inc. Catalog #: sc-8044, dilution:
1:200, molecular weight: 25 kDa); pan-actin (Cell Signaling Technology, Catalog #:
4968, dilution: 1:500, molecular weight: 45 kDa); Caspase 9 (BD, Catalog #: 556585,
dilution: 1:200, molecular weight: 46 kDa).
Statistical analysis
Quantitative analysis was based on the nuclear area, immunostaining results of
activated H2AX, caspase and TUNEL (positively stained cells in situ) as compared
between melanoma with and without nsPEFs Tx. The entire samples along 1, 3,6 and 24
hours post-nsPEF Tx were counted by MATLAB software using fluorescent staining. The
number of positive cells was scored by counting three sets of at least 100 cells under a
microscope. The differences between treated and control groups tested with two-tailed
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Student's t-test and analysis of variance (ANOVA) (SPSS Statistical Programl5.0, SPSS
Inc., Chicago, IL, USA).
Results
H2AX immunohistochemical staining was used as the early test for early DNA
damage. Immunostaining results showed activated H2AX in melanoma with and without
nsPEF Tx at the time 1,3,6 and 24 hours post-nsPEF. It showed a fine programmed time
course of H2AX-positive cells inside melanomas post-nsPEF Tx. Percentages of H2AXpositive cells started to increase 1 hour post-nsPEF Tx, peaked at 3 hours, and then
decreased by 24 hours. The in situ stain is shown in Figure 11 and the quantitative
analysis of H2AX phosphorylation is shown in Figure 12. Six different mice were used at
each time point in each group. The significant increases of H2AX were at 1 hour and
maximum at 3 hours. (p < 0.001 vs. control).
Caspase immunohistochemical staining was tested in melanomas post-nsPEF Tx to
test the pan caspase activation which play essential roles in apoptosis. Time course shows
that percentages of caspase positive cells started to increase 3 hour post-nsPEF Tx,
peaked at 6 hours, and then decreased by 24 hours. Quantitative analysis confirmed that
immunostaining results of activated caspase 3, 6 and 7 positively stained cells in situ and
had a significant increase at 3 and 6 hours post-nsPEF Tx. (p < 0.001 vs. control)
TUNEL immunohistochemical staining was used in melanomas post nsPEF to
detect DNA fragmentation by labeling the terminal end of nucleic acids. Because tumor
cells undergoing apoptosis are characterized by a fragmentation of the genomic DNA,
many breakpoints can be visualized with the TUNEL reaction. The enzyme terminal
desoxynucleotidyl transferase (TdT) adds biotinylated nucleotides to the broken DNA
ends. The biotinnylated DNA can then be visualized by fluorescence label. It showed
that percentages of apoptotic-positive cells started to increase 3 hour post nsPEF Tx,
peaked at 6 hours, and then decreased by 24 hours (Fig. 15). Quantitative analysis
(Fig. 16) confirmed that TUNEL-positive cells showed significant increase at 3 hour and
6 hours (p < 0.001 vs. control)
DNA extracted from treated tumor was analyzed by electrophoresis followed by
ethidium bromide staining for proof of DNA fragmentation. But the typical DNA
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fragmentations, which look like a ladder, were not seen. Only large pieces of DNA were
found.
Mean nuclear area measurement was applied as morphology study as well as a
quantitative analysis to identify nuclear changes. H&E stain showed tumor construction
and nuclear shape changes 1-24 hours post-nsPEF Tx. Control tumor cells exhibited
lightly staining pleomorphic nuclei and abundant cytoplasm containing finely dispersed
melanin granules. Treated tumors had cell with dense staining, shrunken, darken and
elongated nuclei. Cells within the treated melanomas were scattered from the tumor
cord. Intracellular melanin granules as well as aggregated extracellular melanin granules
were scattered throughout the widened interstitial spaces. Quantitative comparison was
made by calculating mean nuclear area (um2) between control melanomas and treated
tumors during 1-24 hours post-nsPEF Tx. A significant difference exists between the
control as compared to lh, 3h, 6h and 24 h post-nsPEF Tx (p < 0.001) as well as between
1 and 3 h times (p < 0.001). The data indicate that immediate changes in the tumor
following the application of the electric field pulses may be responsible for the tumor
regression.
Bcl-2 family protein expression was tested in situ at 3 hours post nsPEF Tx because
Bcl-2 family proteins play a vital role in regulating apoptosis. Expression in situ at 3
hours after nsPEF Tx was determined by immunohistochemistry (IHC). Western-blot
analysis of BAD and Bcl-2 protein expression during 1-24 hours post nsPEF Tx after 100
pulses were applied. The time course showed the amount of BAD increased along the
hours post-nsPEF Tx while bcl-2 decreased. IHC on 3 hours samples showed that the
tumor cells without nsPEF Tx kept the round and regular nuclear shape and size while
melanomas with the nsPEF Tx showed condensed and reduced nuclei. Data showed that
nsPEF increase BAD expression more man control. Bcl-2 was decreased dramatically
after nsPEF Tx. Quantitative analysis of immunohistological staining of BAD and Bcl-2
protein expression showed that BAD was increased while bcl-2 decreased significantly
after nsPEF Tx vs. control (p < 0.001). Caspase 9 expression was tested by western-blot
because it is an important enzyme in extrinsic apoptosis pathway. The time course
showed caspase-9 was activated post-nsPEF Tx.
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H2AX was activated from 1 to 3 hours post nsPEF Tx
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11 - H2AX phosphorylation detected by immuno-fluorescent staining in melanomas post nsPEF
Tx. Immunostaining results of phosphorylated H2AX (positively stained cells) in melanoma with and
without nsPEF Tx were determined 1, 3,6 and 24 hours post nsPEF Tx as indicated. A representative
experiment is shown. Phospho-H2AX-positive signals were indicated byfluorescencein contrast to nuclei.
Phospho-H2AX positive cells are indicated in merged images. Also shown are the corresponding bright
field images. Magnification for lh, 6h and 24h is 200x and the control is 600x.
FIGURE
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12 - Quantitative analysis of H2AX phosphorylation of melanoma tumors during 1-24 hours postnsPEF Tx. Immunostaining results of activated H2AX positively stained cells in situ in melanoma without
and with nsPEF Tx were determined 1, 3, 6 and 24 hours post nsPEF Tx.as indicated in Materials and
Methods. Values are mean±SD. Six different mice were used at each time point in each group * * p < 0.001
p < 0.001 treated (T) vs. control (C).
FIGURE

30

Caspase3, 6 and 7 activation post-nsPEF Tx
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13 - Caspase immunofluorescent staining in melanomas post-nsPEF Tx. Results of
immunofluorescent staining for active executioner caspase-3,6 and/or 7 in melanoma with and without
nsPEF Tx 1, 3,6 and 24 hours post nsPEF Tx are shown as indicated. A representative experiment is shown.
Caspase positive signals were indicated by green fluorescence in contrast to red fluorescence-stained
nuclei. Caspase positive cells are indicated in merged images as yellow-orange. Also shown are the
corresponding bright field images. Magnification is 200x

FIGURE

Caspase

8

C1h

T1h

C3h

T3h

C6h

T6h

C24h T24h

Tim* poat nsPEF* tr«atm«nt (hours)

FIGURE 14 - Quantitative analysis of caspase activation of melanoma tumors during 1-24 hours post-nsPEF
Tx. Immunofluorescent staining results of activated caspase 3,6 and 7 positively stained cells in situ in
melanoma without and with nsPEF Tx 1, 3,6 and 24 hours post nsPEF Tx. Values are mean ± SD. Six
different mice were used at each time point in each group * *. p < 0.001 treated (T) vs. control (C).
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TUNEL result for apoptosis detection
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15 - TUNEL immunofluorescent staining in melanomas post-nsPEF Tx. Immunostaining results of
TUNEL in melanoma with and without nsPEF Tx are shown 1, 3,6 and 24 hours post-nsPEF Tx as
indicated. A representative experiment is shown. Apoptotic tumor cells are characterized by 3' and
5'broken ends of genomic DNA. The many breakpoints can be visualized with the TUNEL reaction (TdTdependent dUTP-biotin nick end labeling). The enzyme terminal desoxynucleotidyl transferase (TdT) adds
biotinylated nucleotides to the broken DNA ends. The biotinnylated DNA can then be visualized by
fluorescence label. Positive signals are indicated by green fluorescence in contrast to red fluorescencestained nuclei. TUNEL positive cells are indicated by the yellow cells in the merged images. Also shown
are corresponding bright field images. Magnification is 200x
FIGURE
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16 - Quantitative analysis of TUNEL in melanoma with and without nsPEF Tx during 1-24 hours
post nsPEF Tx. TUNEL positive cells were determined as described in Material and Methods. Values are
mean±SD. Six different mice were used at each time point in each group. * * p < 0.001 treated (T) vs.
control (C).
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FIGURE 17 - Large DNA fragmentation induced by nsPEF Treatment in melanoma in vivo. B16-F10 cells
incubated with Etoposide used as apoptosis positive control. DNA was analysed by 1.8% agarose gel
electrophoresis followed by ethidium bromide staining. Data are representative of two independent
experiments. B16-F10 cells incubated with Etoposide (Calbiochem, Cat. 341205) used as DNA damage
positive control.
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Mean nuclear area of treated tumor decreased
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18 - Tumor construction and nuclear shape changes 1-24 hours post-nsPEF Tx. Tumors were
treated in vivo with 100 pulses at 300ns and 40kV/cm. Tumors were removed 1, 3,6 and 24 hours post
pulses and prepared for H&E staining Samples at each time point are shown with 40x and lOOOx
magnification. Histological analysis and determination of nuclear areas are described in the legend to
Figure 19 and in Materials and Methods.
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FIGURE 19 - Mean nuclear area (um2) comparison between control melanomas and treated tumors during 124 hours post nsPEF Tx after 100 pulses at 300ns and 40kV/cm were applied. The number of cell nuclei
were measured from 6 mice for each time point and bars represent SEM. Mean nucleus area measurements
was applied as in the morphology study as well as a quantitative analysis to identify nuclear changes.
Specimens were routinely stained with hematoxylin and eosin and analyzed using a computer-assisted
interactive image analysis system MATLAB. Nuclear areas were estimated after manual editing of binary
images. * p < 0.001 treated (T) vs. control (C).

nsPEF Tx up-regulates BAD and down-regulates Bcl-2 expression.

FIGURE 20 - Western-blot analysis of BAD and Bcl-2 protein expression were determined 1, 3,6 and 24
hours post-nsPEF Tx with 100 pulses at 300ns and 40kV/cm. A representative figure of Western-blot
analysis of BAD, Bcl-2 and actin proteins. After nsPEF Tx or non-treated melanoma tumors were collected
and lysed for Western-blot analysis as described in Materials and Methods. Immunoreactivity to b-actin
was used as protein loading control.

35

BAD

Bel-2

21 - Bad and Bcl-2 protein expression and distribution in situ at 3 hours post nsPEF Tx. Bad and
Bcl-2 protein expression in situ at 3 hours after nsPEF Tx was determined by immunohistochemistry (IHC)
using respective antibodies. IHC positive staining is indicated by brown spots overlap the tumor nuclei.
Yellow arrows indicate typical positive cells in IHC stain. The specific procedures are described in
Materials and methods
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22 - Quantitative analysis of immunohistological staining of BAD and Bcl-2 protein expression in
melanoma with and without nsPEF Tx at 3 hours post nsPEF Tx. The positive stained brown cells from IHC
staining were counted and calculated as mean±SD. six different mice with melanomas were tested in every
IHC trial. Statistical significances are indicated. * *p < 0.001 treated (T) vs. control (C).
FIGURE
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Control

1 hour

3 hour

6 hour

24 hour
^-tf>§M$m

caspase 9

actin
FIGURE 23 - Western-blot analysis of caspase 9 expression. Western-blot analysis of active caspase 9 was
determined after nsPEF Tx The melanoma tumors were collected and lysed for Western-blot analysis as
described in Material and Methods. Immunoreactivity to beta-actin was used as internal loading control.

Discussion
When the cells become deregulated, such as during tumor formation, the body can
induce apoptosis to get rid of them by programmed cell death. 53 ' 54 ' 55 In the previous
research in tumor cell lines in vitro, it was shown that nsPEFs induce caspase associated
apoptosis in HL60, Jurkat and HCT116 colon carcinoma by mitochondrial-dependent
(Jurkat and HL-60) and mitochondrial-independent (HCT-116) mechanisms.56 The ex
vivo trial on mouse fibrosarcoma tumors also proved nsPEF Tx resulted in apoptosis as
indicated by caspase activation and TUNEL positive tumor cells. It was further shown
that nsPEF treatment could reduce fibrosarcoma tumor size when treated in vivo51 The
current work was carried out to determine if and how nsPEF induced apoptosis in
melanoma tumors in vivo.
Under certain conditions DNA damage can lead to apoptosis inductions. However,
for stimuli that induced DNA damage, these markers may appear before caspase
activation as a more direct effect on DNA or can occur after caspase activation as
apoptosis markers. Figure 11 clearly indicated that nsPEF induced DNA damage as
indicated by Histone 2AX phosphorylation as a marker for double strand breaks in DNA.
Further evidence for DNA damage was shown by the presence TUNEL positive nuclei
(Figure 15), large DNA fragments by agarose gel electrophoresis (Figure 17) and
shrinkage of nuclei as indicated by H&E histological examination. All of these DNA
damage markers indicated time dependent effects. Histone 2AX phosphorylation and the
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presence of TUNEL positive cells peaked at 3 hours, while the presence of significant
pyknotic nuclei were evident 3-24 hour post pulse. Caspase activation was shown to peak
at 6 hours after nsPEF treatment. These time courses indicate that evidence for DNA
damage occurred before caspase activity was at a maximum. This suggests that some
damage to DNA was in part due to events that were not related to caspase-dependent
apoptosis. This non-apoptotic DNA damage is consistent with the results of Stacy et al.29,
who showed nsPEF-induced DNA damage by comet assay. Further evidence for DNA
damage unrelated to apoptosis was indicated by large fragments of DNA after agarose gel
electrophoresis. Nevertheless, significant evidence for apoptosis is apparently when using
several different apoptosis markers.
Since apoptosis has been demonstrated to occur in response to nsPEFs both in vitro
and in vivo, additional studies were carried out using several different apoptosis markers.
One of the best markers for apoptosis is caspase activation. Here activation of
executioner caspases-3, -6, and -7 was shown using a cocktail of antibodies with
immunofluorescent microscopy. Evidence for caspase activation was obvious 3 hours
post pulse, was maximal at 6 hours, but was not observable by 24 hours after treatment.
Another apoptosis marker is the presence of TUNEL positive cells. However, while some
of the TUNEL positive cells could be related to caspase-dependent activities, at least
some of this occurred prior to the peak of caspase activation. However, caspase-positive
and TUNEL-positive cells were not determined together. Therefore, based on the studies
presented here, it is not possible to correlate caspase activation with apoptosis-dependent
TUNEL evidence. This provides evidence that care should be exercised when using
TUNEL as an apoptosis marker. However, it should be possible to correlate these
apoptosis markers using a more tightly defined time course with assays for caspaseactivated DNase (CAD) activity in cells that are caspase-and TUNEL-positive.
Other evidence for apoptosis in treated tumors was provided by histological analysis
of pyknotic nuclei, which is a good in vivo apoptosis marker. The greatest number of
pyknotic nuclear changes possible occurred between 3 and 24 hours post-pulse. Thus,
some of these nuclei could have occurred due to apoptosis-related activity. The presence
of CAD activity in pyknotic nuclei would help address this issue.
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However, additional apoptosis markers indicated that apoptosis was present in some
of the tumors after nsPEF treatment. Furthermore, since evidence for apoptosis in tumor
cells was present, it was of interest to determine how these processes could be regulated.
Increases in BAD, a pro-apoptotic protein and decreases in Bcl-2, an anti-apoptotic
protein were observed (Figures 20-22). This finding is consistent with a potential shift in
Bcl-2 family proteins toward pro-apoptotic activity. Furthermore, this suggested that the
mitochondria could be involved in nsPEF-induced apoptosis. If this were true, we would
expect to see caspase-9 activation. In Figure 23 evidence for caspase-9 activity was
presented. Thus, the evidences from Figures 20-23 suggest that at least in some tumor
cells mitochondria-dependent apoptosis occurred. This could be due to activities through
the intrinsic apoptosis pathway, which originates from intracellular stresses such as DNA
damage that was observed, or through activities in the type II extrinsic pathway, which
originates from the plasma membrane. At the present time, it is not possible to
differentiate these two processes. In the future, it will be possible to determine the
presence or absence of t-Bid, which connects the extrinsic pathway with the intrinsic
pathway through the mitochondria. This is important regarding nsPEF mechanisms,
which could occur due to intracellular stress or unique effects on the plasma membrane.
If t-Bid were not present it would suggest effects in intracellular structures and functions.
On the other hand, if t-Bid were present, it would suggest effects through the plasma
membrane.
Although DNA fragmentation into DNA ladders is characteristic of apoptosis,58
recent evidence indicates that not all cells undergo such extensive DNA fragmentation.59
NsPEF caused large piece DNA fragmentation instead of DNA ladder. This is because
nsPEF Tx does not affect cells in the same way as a long pulse does. Some sensitive tests
other than the DNA fragmentation was expected to reveal the early stage changes thought
to occur post-nsPEF Tx. TUNEL was used which employs an enzyme TdT (terminal
deoxynucleotide tranferase) to tag the cuts in the DNA made by the endonuclease.
TUNEL was tested on the control tumors and treated tumors. The data showed TUNEL
positive results came at 3 hours, reached its peak at 6 hours, and faded away around 24
hours post nsPEF Tx, This time course is the same as it is for nsPEF-induced caspase
activation.
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It is reported that H2AX phosphorylation occurs where DNA double-strand breaks
by physical attack such as UV or ionizing radiation.60 H2AX phosphorylation is
associated with immediate response to DNA damage and repair. H2AX could be a
marker to indicate an early event in apoptosis, even before the caspase activation and the
DNA fragments form. Therefore, our experiment was grouped into 4 different time
points, 1, 3, 6 and 24 hours post nsPEF Tx with controls to test H2AX activity. These
data confirm the hypothesis that nsPEF Tx triggers H2AX activation as an early response
and it occurs in a tight time sequence. The immune fluorescent stain in situ showed that
H2AX can be demonstrated at the first hour after exposure to nsPEF, reaching a peak at 3
hours and regressing over the next to reach a minimum at 3 hours then fell to a low at 24
h after nsPEF Tx.
Histology changes were recorded the same time course. The previous studies on
long-term biological effects post-nsPEF Tx had found obvious nuclear morphology
changes as well as tumor volume shrinkage. 60 In the current study, histological changes
were confirmed even in the short term. Histology data showed that the nuclear area
began to change slightly from 1 hour post nsPEF Tx, and the cell shrinkage became very
obvious at 3-6 hours. This nuclear change may be the progenitor of the longerterm tumor
remission.
One reason melanoma is resistant to traditional chemotherapy is because melanoma
cells have low levels of apoptosis in vivo compared with other tumors, and are also
resistant to chemical medicine -induced apoptosis in vitro.61'62 Little is known about the
intracellular mechanism involved in nsPEF Tx induced apoptosis in vivo. Because
nsPEF is a new physical therapy made by pulse power technique that does not exist in the
natural environment, nsPEF Tx would work a different way from traditional thermal antitumor therapies.
To summarize, several pieces of evidence indicates nsPEF-induced DNA damage
including H2AX phosphorylation, TUNEL positive cells, nuclear pyknosis as indicated
by H&E staining and large DNA fragments upon agarose gel electrophoresis. Some of
this damage appeared to occur before caspases were activated suggesting that nsPEFs
may induce DNA damage itself. However, it is possible that some of the DNA damage
occurred after caspase activation as part of the apoptosis processes. However, the absence
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of a clear DNA ladder suggests that apoptotic-induced DNA damage did not go to
completion. As indicated in the following chapter, it is possible that an interruption in the
blood supply to die tumor caused tumor infarction, thus interrupting the apoptosis
process. Nevertheless, apoptosis was a cause of some tumor cell death as indicated by the
action of execution caspases as well as the initiator caspase-9. The activation of caspase9, the increase in Bad and the decrease in Bcl-2 suggests that the extrinsic type II
pathway and/or the intrinsic, mitochondria-dependent pathways were activated, at least in
part. The possibilities of nsPEF-induced DNA damage and a possible involvement of the
intrinsic pathway are consistent with nsPEFs affecting intracellular structures and
functions, which has been indicated by modeling and experimental data. ' '
In future work, it will be important to determine if caspase-8 is active and if t-Bid is
present. This will suggest involvement of the extrinsic pathway with caspase-8 and
differentiate between the extrinsic type II and the intrinsic pathway with the presence of
t-Bid.
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CHAPTER IV
NSPEF INHIBIT MELANOMA ANGIOGENESIS IN VIVO
It has been reported that in solid tumor angiogenesis plays an important role in the
growth and metastasis.63 New blood vessels "feed" the tumor cells with oxygen and
nutrients, allowing malignant cells to grow, invade nearby tissue, spread to other parts of
the body, and form new colonies of tumor cells.64 In our initial studies,65 nsPEF Tx
stopped melanoma growth and induced apoptosis. Because melanoma self destruction
was always accompanied with interruption of blood flow, it was important in the present
study to investigate the intra-tumoral vascular response after nsPEF Tx.
In the initial study,65 the major change found in melanomas treated by nsPEF Tx was
immediately and obvious reduction in blood flow to the tumor. Both transillumination
and power Doppler ultrasound reconstructions indicate that the blood flow was stopped
within about 15 min after pulsing. Histology confirmed that red blood cells were found
scattered within and around the melanoma tumor. After weeks the treated melanoma
shrunk to self destruction. The result implies that the intra-tumoral vasculature response
is an indispensable part of mechanisms to make tumor finally self destruct.66 The
hypothesis is tested that nsPEF Tx can cause changes at the molecular level that define
direct pre-existing vessel damage and also inhibit new micro-blood vessel formation.

Material and methods
Animal model
In vivo experiments were set up in conformity with Animal Care and Use Committee
of Eastern Virginia Medical School. Murine melanoma B16-F10 cells were injected
under the skin to induce 2 or 4 tumors in the flanks of 66 female immunocompetent
hairless SKH-1 mice. When the tumors were 5 mm wide and exhibited angiogenesis,
nsPEF was applied on one tumor and the other tumor on the same mouse was kept as
control. Freshly isolated specimens were divided into two series, one was fixed in 10%
neutral buffered formalin overnight and embedded in paraffin for histological analysis,
the other was snap frozen in liquid nitrogen for protein expression tests.
Tissue Micro-arrays Construction
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Tissue Microarrays (TMAs) were adopted for homogeneity and high-throughput analysis
of all samples.67 TMAs were constructed with 0.6-mm diameter cores spaced 0.8 mm
apart. The tissue array consisted of the treated melanomas, control melanomas and
normal skins around the control tumor.
MVD Measurement by CD31, CD34 and CD105 with lmmunohistochemistry (IHC)
One section was stained with H&E for histopathological diagnosis prior to IHC. IHC
was performed as previously described.68 The 5 [im-thick sections were deparaffinized
in xylene and then rehydrated. Slides were treated with 3% hydrogen peroxide for
20 min to block endogenous peroxidase activity. The primary antibodies were used at
the following dilutions: monoclonal rat-anti-mouse CD31 antibody (or PECAM-1, BD
PharMingen), 1:50; rabbit polyclonal anti- CD34 (Biovision), 1:250; rat anti-CD105
(BD PharMingen); 1:200. Then, sections were covered with HRP-conjugated antibodies
directed against rat or rabbit immunoglobulin.69 Nonspecific staining was controlled by
incubation with mouse or rabbit immunoglobulin instead of the specific primary
antibody. 3-amino, 9 ethyl-carbazole (AEC) was used as a chromogen, which provides
the red depositions in situ. The expression of positive cells was assessed independently
by two pathologists, who were blinded to histopathological diagnosis. 70
Western Blot Analysis
Protein was resolved over a 15% polyacrylamide gel and transferred to a
nitrocellulose membrane. The blots were preincubated in blocking buffer (5% nonfat dry
milk, 1% Tween 20, in 20 mM TBS pH 8.0) for 1 h at room temperature, then incubated
with appropriate primary antibodies in blocking buffer from 1 h at room temperature to
overnight at 4°C followed by incubation with anti-rabbit or anti-mouse secondary
antibodies conjugated with horseradish peroxidase and detected by chemiluminescence
and autoradiography using x-ray film.71

Result
Both Tumor blood supply and volume were inhibited by nsPEF Tx
Blood vessels were analyzed first on the pre-existing vasculature . Intra-tumoral preexisting vasculature was recorded by transillumination photography. Melanoma tumors
began with the similar volume and rich blood supply after injection. NsPEF-treated
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tumors had the capillary vessels damage on the day nsPEF applied. Tumors stopped
growing when nsPEF Tx was applied and the vasculature disappeared along with me
tumor shrinkage. Control tumors continued growing with branched blood vessel
network. Transillumination photography recorded the typical procedure. Before the Tx,
melanomas grew to 5-10mm diameters with rich blood supply after injection of 106
B16F10 melanoma cells. One day after the nsPEF Tx, control tumors had blood vessel
networks nourishing active growing tumor cells with a large round nucleus. The same
day in the treated melanoma, the tumor cells became condensed and volume decreased
significantly. The tumor construction was detached, the vessels were broken, and red
blood cells scattered or aggregated into the connective tissue. Seven days after nsPEF Tx,
the control tumors grew to large volumes with rich capillaries and small venules formed
in tumor while the treated tumor dryed out with volume shrinkage and poor vasculature.
Tumor blood vessels post nsPEF Tx were tracked. On the day of nsPEF Tx, the tumor
network didn't change very much, however 3 days later the blood vessel network was
blocked completely. One week later the tumor volume was obviously decreased
significantly. The data altogether indicate that nsPEF Tx damaged the pre-existing blood
vessels.
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FIGURE 24 - Tumor blood supply and volume were inhibited by nsPEF Tx. Four tumors were induced by
injecting B16F10 cells (1x10 ). When the tumors grew to diameters around 5mm, nsPEF Tx was delivered
to three tumors (300 ns, 100 pulses, 40kV/cm, 0.5Hz). One tumor without nsPEF Tx was kept as control.
These four tumors were recorded by transillumination microscopy daily (1.2 x magnifications). The
scaling bar is 2.0mm.

NsPEF Tx cut off the pre-existing vasculature
The treated and control tumors came into the study with the similar tumor size and
rich vessel network. When tumors developed, the accompanying blood supply grew with
it shown as the blood vessels pushed their branches into the tumor. But 7 days postnsPEF Tx the control tumor achieved a considerable volume with good blood perfusion
from arterioles. The treated tumors condensed and the blood vessel dried up. The results
are shown from inner side dissection and the corresponding histology under light
microscopy.
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Histology
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Control

25 - NsPEF Tx cut off the pre-existing vasculature On the 7 day post nsPEF Tx the mice were
euthanized and the tumors were dissected. The tumor and the blood vessels were photographed from the
inner side. The capillaries were analyzed by histology under light microscopy (H&E, 40x). Arrows point to
the pre-existing arteriola and capillaries. Scaling bar is 1.0mm.
FIGURE

Tumor weight decreased in 7 days post nsPEF Tx.
Tumor weight change 7 days post nsPEF Tx was also analyzed. Melanomas grew to
similar weight (control group 1.45±0.15 vs. treated group 1.59±0.12) because the same
amount of B16-F10 cells (lxlO6 cells per tumor) were injected on the same mouse. One
day after the nsPEF Tx, treated tumors became slightly smaller (1.41 ±0.18) than control
(1.61 ±0.25) due to the direct damage of nsPEF Tx. One week later, the control tumor
without nsPEF Tx increased twice in weight (2.71 ±0.17). The treated tumor stopped
growing and ended up with decreased tumor weight (0.58±0.21)(the tumor weight is
Mean ±SD in gram). The treated tumors had roughly five times more weight than the
untreated tumors.
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26 - Tumor weight decreased in 7 days post nsPEF Tx(n=66). The tumor weight is expressed as the
mean +SD in gram. Tumors were induced by injecting the same amount of B16F10 cells (lxlO 6 ). When
the tumors grew to diameters of around 5mm, nsPEF Tx was delivered to three tumors (300 ns, 100 pulses,
40kV/cm, 0.5Hz). On die 7* day post nsPEF Tx, mice were enthanized and the tumors were dissected
along the membrane. The tumors were weighted and the mean value of control tumors and treated tumors
were plotted along the time.
FIGURE

Intratumoral vessel number changes in 7 days post nsPEF Tx
The numbers of intratumoral vessels were counted following staining with H&E
stain. Control melanoma indicated that tumor growth was accompanied by increased
vascularity; the vessel number before the Tx, one day and seven days after nsPEF Tx is
23±3, 32±1,49±2, respectively (Mean±SD). For the treated melanomas, the number of
pre-existing vessels dramatically deceased as 25±2,14±3, 3.0±2, respectively.
(Mean±SD).
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FIGURE 27 - Intratumoral pre-existing vasculature was counted following staining with H& E stain(n=66).
NsPEF Tx was delivered to three tumors (300 ns, 100 pulses, 40kV/cm, 0.5Hz). On the 7th day post-nsPEF
Tx, mice were enthanized and the number of vessels on H&E slides were counted under the microscope.
The mean value of tumor blood vessel number was compared along the time.
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NsPEF inhibit micro-vessel density
In order to clarify angiogenesis after nsPEF Tx, the micro-vascular density was
evaluated through the expression of CD31, CD34 and CD 105, the most common
analyzed 3 markers for angiogenesis. CD31 is known as platelet-endothelial cell adhesion
molecule, which is used as a pan-endothelial cell marker. CD34 is endothelial cell
marker. CD105 is a proliferation-related endothelial cell marker. Figures 28,29 and 30
exhibit typical expression pattern of CD31, CD34 and CD 105 on tissue micro-arrays.
Staining for CD31, CD34 and CD 105 allowed specific detection of micro-vessels in
tissue. Therfore they were used in the current study to estimate the level of functional
blood flow in tumors. In all three stains, control tumors showed red staining spots
(intensive endomelium) which means neovascular hot areas. These spots were further
analyzed under higher power. The red stained areas are endothelial cells or endothelial
cell clusters clearly separate from adjacent non-stained tumor cells, while the treated
tumors showed significant weak intensive endothelium.

NsPEF inhibit micro-vessel density marked by CD31
100X

400X

FIGURE 28 - NsPEF inhibit micro-vessel density marked by CD31. The images include magnifications of
lOOx on the left and 400x on the right, with a control tumor on the top line and a treated tumor on the
bottom line. The darker staining spots are endothelia. A and C are the neovascular hot area under lOOx
magnification. They were further analyzed under 400x magnification in C and D.
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NsPEF inhibit micro-vessel density marked by CD34
100X

400X

29 - NsPEF inhibit micro-vessel density marked by CD34. The images include a lOOx
magnification on the left and 400x on the right, with a control tumor on the top line and a treated tumor on
the bottom line. The darker staining spots are endothelia. A and C are the neovascular hot area under lOOx
magnification, they are further analyzed under 400x magnification in C and D.
FIGURE

NsPEF inhibit micro-vessel density marked by CD105
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30 - NsPEF inhibit micro-vessel density marked by CD 105. The images include a lOOx
magnification on the left and a 400x on the right, with a control tumor on the top line and a treated tumor
on the bottom line. The darker staining spots are endothelia. A and C are the neovascular hot area under
lOOx magnification, they are further analyzed under 400x magnification in C and D.

FIGURE
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The quantitative analysis ofMVD marked by CD31, CD34 and CD105 7 days post
nsPEF Tx vs. control tumor.
Quantitative analysis of immunohistology positive were determined. Decreased
MVD by no matter CD31 (** p<.0001), CD34 (** pK.OOOl) or CD105 (* p<.005), were
noted in nsPEF treated melanomas. The results suggest reduction in the number of
intratumoral micro-vessels in the big, medium or small sized vessels. Because CD31 and
CD34 are pan endothelial markers, all positive stain of micro-vessels, heterogeneous
distribution of large and small micro vessels as well as single immunostained cells
throughout tissue sections were included in the micro-vessel count. As a result, the
difference between the control and treated groups are more significant. CD 105 antigen is
a specific marker of activated endothelial cells. MVD marked by CD105 is for detecting
newly formed blood vessels. IHC staining indicated CD105 positive cells composed of
delicate and ramified vessels. Therefore the CD 105 positive marker is not as significant
as CD31 or CD34 verses control tumor.
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FIGURE 31 -The quantitative analysis of MVD marked by CD31, CD34 and CD 105 7 days post nsPEF Tx
vs. control tumor. Immunohistology positive cells were counted in five different fields, and the mean
number per field was calculated. (**/><.0001), CD34 (**/K.0001) and CD105 (* p<0.05)
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VEGF and PD-ECGF protein expression were decreased by nsPEF Tx
Expression of VEGF and PD-ECGF was analyzed by western-blot. Both VEGF and
PD-ECGF protein expression decreased after the nsPEF Tx compared to the control tumor
from the same mouse (Fig.32).
control

treated

VEGF
beta-actine

control

treated

PD-ECGF
beta-actine

32 - VEGF and PD-ECGF protein expression were decreased by nsPEF Tx. VEGF and PDECGF protein expression was analyzed by Western-blot. Three mice bearing control tumor and treated
tumor were euthanized 7 days post nsPEF Tx. Altogether 7 tumors were dissected. Control tumors (n=3)
and treated tumors (n=4) were included. Beta-actin was used as loading control.
FIGURE

Discussion
The use of pulsed electric fields to reduce tumor angiogenesis has been reported
previously.

Previous research of the anti-tumor effect of nsPEF Tx was confirmed on

murine melanoma in vivo and nsPEF Tx was shown to cause apoptosis which led the
melanoma tumors to self destruct. But nsPEF Tx also caused immediate blood flow
reduction and tumor blood supply decrease. Thus the intra-tumor vascular response to
nsPEF Tx was studied. The hypothesis is that nsPEF Tx can reduce tumor angiogenesis
and might have value as an alternative therapeutic modality for solid tumors with a rich
blood supply.
The vascular response of pre-existing vessels were assessed by histology.73 In this
technique, after the selection of a tumor target area, capillaries were visualized by H&E
stain and the number of vessels per high-power microscopic field were counted. Before
the nsPEF Tx, melanomas were nourished with rich blood supply. One day post nsPEF Tx
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the most obvious effect were blood vessel breakage and red blood cells scattered among
condensed tumor cells with nuclear pyiknosis. Seven days after nsPEF Tx, the control
tumor grew to a large volume with rich capillaries and small venules formed in the tumor
while the treated tumors shrank and exhibited poor vasculature. These results suggest
nsPEF Tx can cause direct damage to the blood vessel. Because of the precise location of
the electrodes and richer vascular network inside the melanoma, the tumor is subject to
greater effects of nsPEF Tx than the normal skin in the area of the tumor. Edema and red
blood cells were evident outside the tumor but they recovered within a week. The treated
tumor shrank with fewer blood vessels and continued to shrink even beyond the acute
damage phase. Therefore beside the direct damage of blood vessel, nsPEF Tx can also
inhibit tumor micro-vessel formation.
Angiogenesis has been proposed as essential for the growth of solid tumors.72
Angiogenesis and the vascular state in tissues are mainly assessed by examining the
micro-vessel density, which can be measured using various specific endothelial markers74.
CD31 has been largely used for immunohistochemical analysis to assess tumour
angiogenesis micro vessel density (MVD). As a panendothelial cell marker it represents
mature vessels.75 CD34 marked medium vessels76 and CD 105 marked newly formed
tiny vessels or neoangiogenesis.77 In our study, no matter what size vessel it marks,
MVD in nsPEF treated tumor always decreased significantly versus control tumor on the
same mouse.
Our results show that nsPEF Tx caused a decrease in VEGF and PD-ECGF
expression, which led to the lower MVD as assessed by CD31, CD34, and CD 105.
However the degree is different. Interestingly CD 105, which is regarded to be a
significant marker of neoangiogenesis, indicate a mild decease which was not as
significant as CD31 or CD34. This difference was caused by the antigen type. CD105,
•
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which is a proliferation-related endothelial cell marker, reflects active angiogenesis.
is a specific marker of activated endothelial cells. In IHC, it recognized tiny newly
forming blood vessels. Because CD34 and CD31 are expressed on most endothelial
capillaries, they are termed pan-endothelial markers.69 In IHC, they stained most
endothelial cells and also positive for some other mesenchymal cells.

It
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In vitro data suggest that VEGF over expression is a common phenomenon of
melanoma cells. 80 Up-regulation of VEGF and hence increased angiogenesis—has been
recently shown in melanoma cells undergoing malignant transformation induced by over
expression of the survival signaling protein Akt in v/vo.81
Angiogenic cytokines, released by tumor cells have an effect on vessel formation,
tumor growth and metastasis;

The balance of pro-angiogenic and anti-angiogenic

cytokines determines whether endothelial cells remain in angiogenic homeostasis,
retrogression, or proceed to the state of neovascularisation to promote tumour growth,
migration and metastasis.83 Since nsPEF Tx can not only affect pre-existing vessels, but
also micro-vessels, the hypothesis is that nsPEFs act on the angiogenic cytokines and
changed the balance between pro- and anti-angiogenic factors.
Although many important promoters of angiogenesis have been reported, the most
heavily studied one is VEGF,84 apparently the most important angiogenic factors. It is a
specific mitogen for endothelial cells and induces capillary tube formation, and increases
vascular permeability. It regulates both physiological and pathological angiogenesis in
melanoma. In the present study decreased VEGF expression is noted in nsPEF treated
melanomas, VEGF was inhibited and expressed less after nsPEFs Tx. It contributes to
the corresponding low angiogenic activity. The decreased VEGF expression led to
recessive capillary proliferation and therefore neovascularization in melanoma was
accordingly down regulated.
Platelet-derived endothelial cell growth factor (PD-ECGF) is a potent angiogenic
factor that has been shown to be a thymidine phosphorylase. This enzymatic activity is
crucial to its angiogenic activity.85 PD-ECGF also showed decreased expression in the
nsPEF treated melanomas.
One limitations of this study is the length of the follow up period. To set up a strict
control, two melanomas were injected on the same mouse to avoid tumor growth
difference originating from immune discrepancy between individual animals. However
it's necessary to enthanize the animal before the control tumor exceed the maximum
tumor burden in the animal protocol (2cm or appearance of ulceration). Nevertheless,
despite the relatively short follow up period (7 days post nsPEF Tx), the results
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demonstrate a significant impact of nsPEF Tx on the intra-tumoral vessel histology, MVD
and the expression of VEGF and PD-ECGF.
It is specifically interesting that nsPEF Tx affected both immediate and delayed blood
vessel effects, most likely as a result of several different mechanisms. One of these could
be due to direct electric field effects on small blood vessels. Immediate effects on
smaller vessels were greater than effects on larger vessels. This would be likely in the
event of very high electric fields. Another possibility could be due to apoptosis, which
has been shown to occur as early as 3 hours in fibrosarcoma tumors ex vivo (Beebe et al.,
2002, IEEE). Likewise, nsPEF induced apoptosis in B16fl0 tumors in vivo in the same
time domain. Thus it is possible the nsPEF Tx induced apoptosis in endothelial cells to
account for delayed effects on tumors vessels. In fact, the presence of apoptosis in
endothelial cells from adipose tissue has been observed (S Beebe, unpublished, personal
communication). Another possibility is effects on vasovasorium, the small blood vessels
that provide blood to large vessels. Effects on PDGF and PD-ECGF are most likely do
the effects on tumor cells that re-direct their energy supplies to apoptosis as opposed to
growth factor production.
Tumors need nutrients and oxygen supplied by blood vessels in order to grow.
They also use blood vessels to spread to other parts of the body. This process, known as
metastasis, is the most lethal stage of cancer and the leading cause of cancer-related death.
Fighting cancer by starving tumors of life-giving blood vessels has generated great
interest in recent years. "Anti-angiogenic" cancer therapies that focus on the tumor's
blood supply are not new. However, other such treatments starve tumors of their blood
supply indirectly, by reducing blood vessel growth signals.
To summarize, nsPEF Tx directly damaged the melanoma cells and pre-existing
blood vessels. As a result, tumor-derived blood vessel growth factors such as VEGF and
PD-ECGF were decreased and the balance between pro-angiogenic and anti-angiogenic
cytokines was broken. These changes resulted in the inhibition of the new vessel
formation. The shortage of blood nourishment induced (1) the tumor infarction and
consequently (2) less phagolysis, which interacts with apoptosis and contribute to the
melanoma self destruction.
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CHAPTER V
TEATMENT WITH NSPEF PROVES LONG-TERM EFFECTIVENESS FOR
MELANOMAS IN MICE
Previous research with nsPEFs included 120 mice treated with 100 pulses of 300 ns
duration with 40 kV/cm field strength.

Observations lasted from 2-4 weeks. These

short-term studies showed that nsPEF with a 30 nanosecond rise time caused melanoma
tumor cell nuclei to rapidly shrink and also to decrease blood flow to tumors. Melanomas
shrank by 90% within two weeks. The treatment caused minor surface skin eschars with
edema in the treated area that recovered in 7-10 days. NsPEF Tx deposited energy of 0.2
J/pulse and 100 pulses increased the temperature of the treated region by 3 °C, 10 degrees
below hyperthermia threshold damage.

However, the mice were routinely euthanized

within a month of treatment for histological analysis. For this study, post-nsPEF treated
mice were being observed for 3-5 months as a long-term survival study following
complete tumor regression.
Materials and Methods
Tumor Model
In vivo experiments were set up in conformity with IACUC guidelines under
applicable international laws and policies (Animal Care and Use Committee of Eastern
Virginia Medical School IACUC #06-011). In accordance with principles for the ethical
use of animals, the smallest number were used to obtain statistically meaningful data.
Thirty-six immunocompetent hairless female SKH-1 mice (albino strain, Charles River,
Wilmington, MA, 4-week old) were injected subcutaneously with 10 ul PBS containing
lxl0 6 B16-F10 murine melanoma cells. Before treatment, the mice were randomly
assigned to 2 groups88 (17 in the treated group and 19 in the control group).
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FIGURE 33 - Melanoma-FlO cells in culture and tumor cell injection on SKH-1 mouse. Left murine
melanoma B16-F10 cells in culture during log phase (400x). Right B16-F10 melanoma cells being injected
under skin of female SKH-1 mouse.

Nanosecond Pulse Generation
The nanosecond pulse generation has an impedance of 75 Q. and consists of 30
pairs of high-voltage capacitors and 30 inductors arranged in a Blumlein configuration.
This construction generates a square wave, 300 nanosecond, high-voltage pulse. The
voltage across the tumor was monitored using a high voltage probe (P6015A, Tektronix,
Beaverton, CA), and the current was measured by means of a Pearson coil (model 2877,
Pearson Electronics Inc., Palo Alto, CA). Current and voltage were recorded
simultaneously using a digitizing oscilloscope (TDS3052, Tektronix, Beaverton, OR). A
single pulse had a duration of 300 ns, field strength of 40 kV/cm at a rate of 0.5 Hz.
Pulse Treatment
Seventeen mice were treated 1-4 times with 300 pulses at 40kV/cm. Each
individual treatment of 300 pulses was separated by 2 weeks during which time the tumor
was evaluated for nsPEF effects. If the tumor was alive either on the surface by
transillumination or by ultrasound imaging at the end of the 2-week interval, another 300pulse treatment was ordered. For tumor remission, one mouse needed one treatment (7%
of the total), two mice needed two treatments (14%), nine mice needed three treatments
(65%) and two mice needed four treatments (14%). Euthanasia and tissue collection
start-time was calculated from the last treatment day.
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In vivo Imaging
Melanomas were imaged daily by external skin surface, transillumination and
ultrasound (Visualsonics Vevo 770, Visualsonics Inc., Toronto, Canada) with model 708
scan head at 55 MHz. The power Doppler mode provided blood flow images for each
tumor. Pictures were taken every 1-2 days and tumor volume was estimated as O'Reilly
experienced equation [V = (tumor width)2 x (tumor length) x 0.52] .90 Vessels supplying
the tumor were counted under transillumination microscopy.
Survival Analysis
An animal survival curve (Kaplan-Meier plot) was analyzed using a log-rank test.
Differences between treated and control groups were considered as statistically
significant at/? < 0.05. Statistical analyses were done using SPSS 15.0 software.
H&E Staining
Mice were euthanized by CO2 asphyxiation under anesthesia and dissection was
performed under aseptic conditions to collect tumor with overlying skin, liver, lungs and
spleen. A red tattooing ink was used to mark tumor location at tumor cell injection
sights. Melanoma samples were processed for histology and immunohistochemistry.91
Data Collection
After five days post-injection of tumor cells, data were collected every day and
summarize according to 5 different time periods (Tl - T5): Tl- corresponds to the time
of injection to time to treatment; T2- corresponds to the time of final treatment; T3corresponds to one week post-final nsPEFs treatment; T4-corresponds to 2 weeks postfinal nsPEFs treatment; T5-corresponds to the final week prior to animal euthanasia (end
of study). The control group data analysis followed the same time course. In summary,
Tl = injection, T2 = end of treatment, T3 & T4 = 1st and 2nd week after last treatment
respectively and T5 = euthanasia.
Tissue Micro-array Construction
Representative areas of the different lesions were carefully selected on H&E-stained
sections and marked on individual paraffin blocks. Two tissue cores (1 mm diameter)
were obtained from each specimen. In addition, non-neoplastic melanoma control tumor
samples were included as controls. Tissue cores were precisely arrayed into a new
paraffin block using a TMA workstation (Beecher Instruments, Silver Spring, MD). An
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H&E-stained section was reviewed to confirm the presence of morphologically
representative areas of the original lesions.
Histology and Immunohistochemistry for Micro Vessel Density
Six um-thick, paraformaldehyde-fixed, paraffin-embedded tumor, liver, spleen or
lung sections were analyzed. Specimens were deparaffinized, rehydrated and processed
for either histology or immunohistochemistry. The antibodies used for blood vessel
immunohistochemistry were an anti-mouse PECAM/CD31 polyclonal antibody (M-20;
Santa Cruz Biotechnology, Santa Cruz, CA) used at a concentration of 2 ug/ml for 2
hours at 37°C, for 1 hour at room temperature. In negative controls the primary antibody
was omitted. The signal was revealed by AEC staining (3-amino-9-ethylcarbozole, red)
instead of DAB (3, 3'-Diaminobenzidine, dark brown) to avoid confusion of melanin.
Micro-vessel counts were performed on CD31 positive-stained blood vessels.
Western Blotting Analysis for CD31 Expression in Melanomas
The melanoma samples were digested in hypotonic buffer (10 mmol/L Tris-HCl, 1
mmol/L ethylenediaminetetraacetic acid, pH 7.4, with protease inhibitor cocktail tablets;
Complete, Roche Diagnostics, Basel, Switzerland). An aliquot of extract was saved for
determination of protein concentration and the remainder was boiled in the sodium
dodecyl sulfate loading buffer. Eighty ug of protein per sample were separated by 6%
gel electrophoresis and transferred to a nitrocellulose filter (Amersham Life Science,
Buckinghamshire, UK). Protein detection used (1) a rabbit polyclonal antibody against
CD31 (Beijing Boisynthesis Biotechnology CO., LTD) that recognizes both murine and
human forms of the receptor and (2) a monoclonal antibody against P-actin diluted
1:1000 (AC-40, Sigma-Aldrich). Detection was performed through a chemiluminescence
assay (ECL; Amersham Life Science).

Results
Long term survival analysis
To establish the role of nsPEFs in inhibiting tumor growth in vivo, B16-F10
melanoma cells were injected intradermally into the flank of SKH-1 mice (n = 36).
Tumor size was measured daily beginning 5 days post-injection of tumor cells when the
tumor mass began to be detectable. Control mouse tumors (n = 19) grew exponentially
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throughout survival time with dramatic acceleration as compared to nsPEF-treated
animals (n =17). A significant difference was already readily detectable in the 1st and
2nd week after nsPEF Tx. At the experiment's conclusion, melanomas were eliminated
in all 17 experimental mice treated by nsPEF and they survived 3-5 months following
visible remission. In contrast 13 of the total 19 controls were euthanized within several
weeks of B16 cell injection because growth exceeded prescribed size or tumor became
ulcerated.94 In some of these studies, mice were used that were more mature than other
mice. These mice were more likely to survive tumor initiation and progression than mice
that were younger due to a more mature immune system. It is likely that these mice were
responsible for control animal survival greater than 180 days. It should be noted that the
tumors in control animals did not decrease in size, but remained at a level that was not
deleterious to the animals health as defined by the IACUC protocol.

FIGURE 34 - Melanoma Growth Inhibition and Survival Time Post nsPEF Tx. Bars with mouse ID froml-17
indicate animals that were treated. Survival days ranged from 117 to 169. Bars with mouse ID from mouse
#19-36 indicate animals that were non-treated controls.
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Mouse weighs change during the 5-month survival study

1

2

3

4

5

1

2

3

4

5

FIGURE 35 - Mouse weight follow up during the 5-month survival study. Group 1, treated animal and group
2, control animal. Five boxes in each group represent time period 1-5. Time 1 is injection, time 2 is
treatment, time 3 and 4 are the 1st and 2nd week after the last treatment and time 5 is euthanasia. The
hinges at the top and bottom of the box generally match the upper and lower quartile of weight
measurement of each group. The median is indicated by a thick black line inside the box. The horizontal
lines above and below the boxes mark the adjacent values. These are the most extreme values in the sample
that lie between the hinges and the inner fences. Data points outside this range should be considered as
outliers. Any outliers are marked with a circle and extreme cases with an asterisk.

Tumor volume change after the treatment
When the data was analyzed, the mean value was gotten from 5 time periods which
are defined in the legend to Figure 35: Mouse weight change after the nsPEF Tx was
measured daily in 5-month survival study. The treated group showed a significant smaller
mean weight. A typical tumor morphological change was reflected by surface photograp.
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36 - A Typical tumor morphological change reflected by surface photograph. Melanomas were
imaged daily and tumor size and appearance were recorded. Time 1 is injection, time 2 is treatment, time 3
and 4 are the 1st and 2nd week after the last treatment and time 5 is at euthanasia. The scale bar is 2mm.
FIGURE

Statistical analysis for tumor volume changes in long term survival study after the nsPEF
treatment
Melanomas were imaged daily and tumor volume was calculated by the formulation
V = (tumor width)2 x (tumor length) x 0.52. After the injection both groups showed die
tumor growth with increased tumor volume. NsPEF Tx changed the growing and tumor
volume decreased significantly (p=0.0004).

50.00-

'

time

•
0

1.00
2.00
3.00

• i 4 °°

• s.oo

*

30.00-

ZO.OO-

10.00-

o.oo-

ji?M

*'K

m

^

1

4

S

2

3

1 2

3

4

37 - Statistical analysis for tumor volume changes in long term survival study after the nsPEF
treatment. Melanomas were imaged daily and tumor volume was calculated by the formulation: V =
(tumor width)2 x (tumor length) x 0.52. Group 1, treated and group 2, control. Time 1 is injection, time 2 is
treatment, time 3 and 4 are the 1 st and 2nd week after the last treatment and time 5 is at euthanasia.

FIGURE
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Histological analysis of tumor structure in long-term in survival study
Histological analysis demonstrated that melanomas in the control group were large,
round and stuck out of the skin surface. In most cases, the tumors were separated from
the overlying epidermis by a thin zone of dermis that appeared highly vascularized. The
skin above the big control melanoma mass was often ulcerated, but ulceration did not
correlate with a shorter life span. Tumor cells were large with eosinophilic cytoplasm
often containing an accumulation of melanin pigment and atypical vesicular nuclei with
prominent nucleoli. In comparison, melanomas were hard to find in all 17 treated
animals unless a small amount of melanin pigment was left in the tattooed skin area.
Tumor net construction and tumor blood supply were totally destroyed with no evidence
of the tumors remaining. Only a few masses of atypical melanoma cells were located in
the area.
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FIGURE 38 - Histology analysis of tumor structure in long term in survival study. The left panel represents a
typical treated tumor and the right panel represents a typical control tumor. An area was magnified to 400x
to show the tumor cell details in both panels.
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NsPEF decreases peritumoral vascularization in long- term survival study
Macrographs revealed that the melanoma mass in control animals was surrounded
by an extended area of prominent vascularization while the opposite was found in the
treated group, which exhibited a very poor blood supply without surrounding visible
vessels at the end of the study.

39 - NsPEF decreases peri-tumoral vascularization in long-term survival study. Treated tumors are
shown in the top row and control tumors in the bottom. Treatments 1-5 are: Time 1 is injection, time 2 is
treatment, time 3 and 4 are the 1st and 2nd week after the last treatment and time 5 is at euthanasia. The
scale bar is 2mm.
FIGURE

Quantitative analysis ofperitumoral vascularization change in long term survival study
after the nsPEF treatment
Vessel number around tumor showed no difference in control vs. treatment groups
before nsPEFs treatment (time 1 and time 2) while there were statistical difference after
the nsPEF Tx (time 3, time 4 and time 5). Treated tumors analyzed beyond 1 week posttreatment were greater than 6-times smaller than control tumors.
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FIGURE 40 - Quantitative analysis of peritumoral vascularization change in long-term survival study after
the nsPEF treatment. Vessels around tumor were counted with transillumination microscope and then a
mean value was summarized according to the time segment as mentioned above. If there were many blood
branches, only those going directly into the tumor were counted. Time 1 is injection, time 2 is treatment,
time 3 and 4 are the 1st and 2nd week after the last treatment and time 5 is at euthanasia. A t-test analysis
showed vessel number around tumor exhibited no difference before nsPEFs treatment (time 1 and time 2),
while there was statistical difference after the nsPEFs treatment (time 3, time 4 and time 5).

Metastatic analysis of melanoma tumors in long-term survival study post-nsPEF Tx
H&E staining of lung, liver and spleen showed metastatic nodules in control mouse
ID 196, while in nsPEF treated mouse ID 189, only the liver exhibited metastasis,
however, lung and spleen did not exhibited metastasis. For the statistical analysis, the
metastatic rate between treated (1/17 and positive rate 5.8%) and control groups (1/19,
5.3%) showed no difference.
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41 - Statistic analysis of melanoma tumors in long-term survival study post-nsPEF treatment.
Treated tumor ID 189 is shown in the top panel and control tumor ID 196 is shown in the bottom. H&E
staining of lung, liver and spleen are shown as indicated. Original magnifications, x400.
FIGURE

Angiogenetic analysis of melanoma tumors in long-term survival study post-nsPEF Tx
Tumors from thirty six mice and the lungs, liver, kidney and spleen were put on one
tissue-micro array slide for H&E analysis.

H&E staining showed the treated tumor had

no cancer cells left in the tumor area, only some melanin. The immunohistochemistry
(IHC) can show quantitative and qualitative differences in the vasculature of the control
and treated tumors by CD31, the pan marker for micro-vessel density. Control tumors
had significantly more vessel lumens and capillary endothelial cells than the treated
tumor per microscopic field (p<0.001). This result was also confirmed by CD31 protein
expression by Western-blot which showed high CD31 expression in control tumors (n=3)
and low expressed in treated tumors (n=2).
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FIGURE 42

- Angiogenesis analysis of melanoma tumors in long term survival study post nsPEF treatment.
Angiogenesis was analysis by tissue micro-array and H&E staining. All the tissues collected were
constructed on a tissue micro-array so that the same tests were applied to all the samples in the following
IHC analysis.
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43 - Micro vessel density marked by CD31 with immunohistochemistry of melanoma tumors in
long-term survival study post nsPEF treatment. Vasculature within melanoma in SKH-1 female mice.
B16F10 mouse melanoma cells were injected subcutaneously into mice, and tumor vasculature was
examined by using immunohistochemical staining with anti-CD31. H&E staining showed the tumor
volume decreased after nsPEF treatment. Frozen sections of tumors were stained with mouse monoclonal
anti-CD31 antibody for total vessel count. The IHC can show quantitative and qualitative differences in the
vasculature of the tumors. Micro-vessel counts were performed at x200 magnification in five microscopic
fields. AEC positive staining showing new micro vessels formed inside the tumor. The melanin is a sign of
malignant melanoma tumor cells. Positively stained blood vessels by CD31 with lumen as well as cell
clusters without a lumen and single cells were considered as individual vessels.
FIGURE
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FIGURE 44

- CD31 protein expression by Western-blot of melanoma tumors in long term survival study
post-nsPEF treatment. Western blot showed high CD31 expression in control tumor (n=3) and low in
treated tumors (n=2).

Discussion
Nanosecond pulsed electric fields can induce various kinds of biological effects that
are essentially different from conventional plasma membrane electroporation with lower
electric fields and longer pulses, 95especially the interactions of nanosecond pulsed
electric fields with living cells.96 Based on these effects, some applications of pulsed
electric fields in cancer therapy, gene therapy, and delivery of drugs were reviewed in
details.97
However most investigations of the effects of nsPEFs on mammalian cells were in
vitro studies. The previous in vivo study, which involved nsPEF treatment of murine
fibrosarcoma tumors indicated the short term biological effects of nsPEFs on tumor
including apoptosis markers for caspase activation and TUNEL. However, longer term
effects were not considered. In the studies reported here, the data suggest that nsPEFs
eliminate tumor by apoptosis and decreased peritumoral vascularization.
Survival curves reflect an obvious difference between the treated and control
groups. The accumulative survival rate in treated group was 100%, with all 17 mice
living 3-5 months after melanoma tumors vanished. In contrast, 12 control animals died
in 17 days for the large tumors including those that were ulcerated. The therapeutic effect
of nsPEFs comes from its unique character of high power and low energy density (nonthermal). The nanosecond pulses are too short to cause plasma membrane
electroporation. Instead they modulate intracellular structures and functions and work as
a form of non-ionizing radiation and are special for cancer treatment because of faster
rise time (30 nanosecond) and shorter pulse duration (300 nanosecond).The charging time
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on the cell membrane is so short that it can penetrate into the cell interior.

The

hypothesis is that the internal field will generate a current that can kill the tumor cells and
blood vessels by the large field strengths (40KV/cm).
The data here also showed statistic change of tumor volume and blood supply.
Tumor growth and metastatic spreading depends on the formation of new blood vessels
i no

that provide oxygen and nutrients.

To promote new vessel development, tumor cells

secrete angiogenic growth factors that act on the neighboring endothelial cells, inducing
proliferation and migration.101 According to the histology, nsPEF destroyed the tumor
and blood vessel at the same time. Our transillumination pictures showed that adult
vessels around the tumor decreased dramatically after nsPEFs treatment. The vessel
structure was damaged and bleeding could be seen. After multiple nsPEF Tx, no visible
tumor and blood vessel could be found. B16F10 melanomas are highly invasive in part
because formation of micro vessels is very efficient. It is clear that micro vessels play a
very important role in metastasis. It has been reported that intratumoural microvessel
density (MVD) marked by CD31 has prognostic significance in melanoma. To evaluate
MVD in nsPEFs treated and control melanomas, the immunohistochemical expression of
CD31 was assessed using the tissue micro-array technique so that all samples could be
tested under the same condition. CD31 expression was significantly, higher (p< 0.001) in
control group compared to nsPEFs-treated group. Also CD31 protein expression was
tested by immunoblot analysis confirming and the result agreed with the IHC findings.
Tumor angiogenesis is a complex phenomenon that depends on the action of proand anti-angiogenic factors, proteinases and their inhibitors, and adhesion molecules.
Endothelial cells are able to secrete their own growth factors, but also other cell types,
including tumor cells, cells of the tumor stroma and infiltrating inflammatory cells could
produce factors that stimulate angiogenesis.102 NsPEF treatment is non selective on cell
type and it targets all cells in the plate electrode area. NsPEF damaged both endothelial
cells and tumor cells and as a result, the angiogenetic function is hindered. It is highly
likely that the direct damage to blood vessels and tumors is a major mechanism to stop
tumor growth. However, the effects of nsPEF are non-thermal and does not cause a heat
response from tumor and the normal tissue around the treated areas are not affected by
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thermal changes. In a previous study, the mild bleeding and edema around the plate
electrode was found, but recover in one week.
Application of nsPEFs makes a significant difference on tumor volume and blood
supply. However, effects on metastasis showed no difference in control and treated
group. The reason for absence of metastasis in this study is likely due to the injection of
B10F10 cells subcutaneously instead of via tail vein.103 B16F10 is very metastatic when
injected into the circulatory system,104 but not so invasive when implanted as a solid
tumor. This may be why so few metastatic sites were found (in 36 mice only 2 cases of
metastasis found). An isolated sub-line, BL6 is very aggressive in metastasizing from a
solid tumor but less so from direct injection into veins.105 B16F10 line used here may
lack mutations in genes that facilitate tissue breakdown, which they must have to escape
the primary tumor. If they are injected instead in the tail vein, they will bypass the need
for tissue breakdown and proceed rapidly to metastasis.106
Because of the low metastasis rate in control tumor group, the study can not provide
strong proof for anti-metastasis effects of nsPEFs. The weight difference between control
and treated mice is not very meaningful even though the data showed that the weight of
the nsPEF treated group had decreased statistically. Because the treated group lived 3-5
months, the SKH-1 mice began the experiment when they were 4-week old and had
plenty of time to gain weight. While most of the control group just died in 2-3 weeks
after the B16F10 injection, their time to gain weight was negligible. The present survival
study for metastasis issue is therefore incomclusive. But the metastasis issue can be
further studied in future trials with the more aggressive melanoma cell lines.
Nevertheless, the metastasis issue does not detract from the fundamental conclusion that
nonthermal nsPEF Tx can cause electrical, biochemical, functional and histopathological
changes in melanomas in vivo and in long-term studies, tumors did not reoccur at the
primary site.
In summary, melanoma is a malignant skin cancer, which causes the most skin
cancer-related deaths in humans. In its advanced stages melanoma is resistant to existing
therapies. The effect of a unique non-thermal nsPEF Tx on murine B16F10 melanoma
cells in vivo in a long-term survival study provides evidence for long term survival. The
data showed that nsPEF Tx can decrease tumor volume and blood vessel number and
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finally total tumor elimination, not returning to the primary site after 3-5 months. The
survival days for the treated group are significantly different from control group. This
suggests that nsPEF Tx could be used as a therapeutic treatment for melanoma and
furthermore its long-term effectiveness is proved.
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CHAPTER VI

PARAMETER STUDY OF NSPEF
In the former experiments, the primary objective was to see if nsPEF Tx had any
effects on in vivo melanomas. Thus the same treatment condition was used from
preliminary experiments: pulse duration was 300 ns, pulse number was 100, the electric
field was 40 kV/cm and the frequency was 0.5 Hz. The data confirmed that this
condition caused apoptosis, inhibited angiogenesis and eliminated the tumor. Only the
treatment conditions mentioned above were used. Different treatment conditions for
pulse number, energy density and pulse duration may result in different values of
biological responses. Therefore the parameters were changed to study the corresponding
biological effects. First, for all conditions tested the energy density was kept at the same
level, but the pulse duration was varied to compare how longer pulses (1ms) and shorter
pulses (300 ns) affected tumor growth. Second, the pulse duration was kept as 300 ns
while the voltage and pulse number was changed to see if there was a dose-effect
relationship.
Material and Methods
Electrical conditions for nanosecond pulse and millisecond pulse
Eight mice bearing tumors derived from B10F10 GFP (green fluorescence protein)
cells were studied to compare long pulses (pulse duration 1ms) with short pulses (pulse
duration 300 ns). Five days after the subcutaneous injection of 1 x 106 B16F10 GFP cells
were injected and tumors having a mean diameter of 5 mm were treated. The same
electric energy was delivered to 2 tumors injected on the left and right flanks of the same
mouse but one treated with a long pulse (1ms, 150V, 48 pulses) and the other with a short
pulse (300ns, 6kV lOOpulse). The animals were euthanized and dissected tumors were
visualized by florescence microscopy.
Quantification ofcaspase-3 enzymatic activity
Melanomas were placed on dry ice (5-10 min) and lysed in Tris buffer with 0.5%
Triton, pH 7.5, containing general protease inhibitors. An aliquot was diluted with a
solution containing interleukin IB converting enzyme (ICE) buffer and the fluorogenic
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caspase-3 enzymatic activity was determined by Ac-DEVD-AFC (N-acetyl-aspartateglutamate-valine-aspartate-AFC, 7-amino-4-trifluoromethyl coumarin) ,107 Fluorescent
emission (excitation 400 nm and emission 505 nm) was measured after incubation for 45
min at 37°C. Blanks were evaluated to determine background fluorescence. Standards
containing 0-500 pmol/1 AFC were used to determine the amount of fluorochrome
released. Fluorescence was measured at Amax = 505 nm using a SpectraMax Gemini XS
(Molecular Devices, Sunnyvale, CA, USA). Caspase activity was expressed as
pmol/min/mg protein. Murine melanoma B16F10 treated with 1 mmol/1 cycloheximide
were used as positive controls.
Fluorescent tumor model
To compare the long and short pulse differences clearly, B16F10 cells were replaced
by a B16F10 GFP cell line, which continually expresses the GFP protein.108 Because
melanomas derived from this cell line were clearly detected under the animal's skin upon
fluorescent microscopy, tumor margin and tumor volume were easily defined. This
enabled in vivo imaging of the tumor volume and fluorescence intensity over time after
treatment.109 These tumor cells have an expression of GFP gene less than 100%, but the
majority do have green fluorescence which makes this animal model able to provide the
green fluorescence quenching as a biological effect.

Results
Comparison of long pulse and short pulse.
Before pulses were delivered, the tumors had bright green fluorescence. When the 1ms PEF (150v, 48 pulses) was applied to the tumor, GFP quenching happened
immediately. In contrast, when the 300-ns PEF (6 kV, 100 pulses) was applied to the
tumor, the GFP began to fade gradually. After 3-6 hours most of the green fluorescence
disappeared. After 24 hour post-nsPEF Tx the fluorescence vanished. This time
sequence matches caspase activation, TUNEL detection and histological changes, which
were discussed in Chapter III. Thus, both pulse conditions had quenching effects on
tumor, but the long pulse effect was immediate, suggesting a direct effect on GFP
fluorescence. In contrast, the short pulse effect on quenching was delayed and coincident
with apoptosis, suggesting that the GFP was degraded with other proteins in response to
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apoptosis. Furthermore, the short pulse conditions inhibited the tumors more effectively
then the longer pulse conditions.
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45 - Long pulse effects on fluorescent melanoma tumor cells in vivo. Digital imaging was used to
quantify the relative fluorescence of B16F10 GFP tumors at the different time points. The images show
GFP fluorescence with times between 1-180 minutes. The surface view and the dissected view are also
shown in the same time course. Scale bar is 2mm.
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46 - Short pulse effects on fluorescent melanoma tumor cells in vivo. Digital imaging was used to
quantify the relative fluorescence of B16F10 GFP tumors at the different time points. The images show
GFP fluorescence with times between 1-72 hours. Surface views, dissected views, and transillumination
views are also shown in the same time course. Scale bar is 2mm.
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47 - Tumor volume and GFP fluorescence changes before and after PEF treatment. The figure
shows effects of the long and the short pulses on tumor volume and GFP fluorescence as a function of time
after pulse treatment as indicated in the color code (n=4, p<0.05). The long and short pulses were adjusted
to the same energy density.
FIGURE

The in vivo tumor didn 't hold the scaling law
When cells in culture were exposed to pulse conditions that differed in pulse duration,
electric field and/or pulse number, it was found that a linear relationship was observed
when the data were plotted for nsPEF effect on calcium mobilization and platelet
activation versus the product of the pulse duration, electric field, and the square root of
the pulse number. This provided a scaling law that described effects of nsPEFs in vitro.
In the experiments here, the scaling law was tested by varying pulse number and electric
field under 9 different treatment conditions (Table II -Table VI). The biological effects
were evaluated by caspase 3, a marker for apoptosis and CD31, a marker of micro-vessel
density for angiogenesis. Tumor volumes were also plotted. A linear relationship was not
observed when plotted against this formula for caspase activation, CD31 expression, or
tumor volume.
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TABLE II - DIFFERENT LEVELS OF ELECTRIC FIELD, ENERGY DENSITY AND
PULSE NUMBER
E
lOkV/cm
20kV/cm
40kV/cm

Pulse duration
300
300

Pulse number
10
100

300

300

TABLE III - THE RANDOM COMBINATION OF DIFFERENT NSPEF
TREATMENT CONDITIONS
Condition

Sample number

E (kV/cm) T(ns) n

1
2
3
4
5
6
7
8
9

2
2
2
2
4
2
2
8
8

10
10
10
20
20
20
40
40
40

300
300
300
300
300
300
300
300
300

10
100
300
10
100
300
10
100
300

EtVn
9480
30000
51962
18960
60000
103800
37920
120000
207600

TABLE IV-CASPASE ACTIVITY MEASURED BY AC-DEVD-AFC UNDER
DIFFERENT NSPEF TREATMENT CONDITIONS
Caspase-3
Condition
E(kV/cm)
x(ns)
n
ExVn
pmol/minute/mg
protein
1

10

300

10

9480

51

4

20

300

10

18960

91

2

10

300

100

30000

49

7

40

300

10

37920

32

3

10

300

300

51962

83

5

20

300

100

60000

171

6

20

300

300

103800

64

8

40

300

100

120000

129

9

40

300

300

207600

98

76
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FIGURE 48 - The plot of caspase activity under 9 different nsPEF Tx conditions against the indicated X-axis
formula.

TABLE V - CD31 PERCENTAGE OF POSITIVE CELLS IN EVERY FIELD UNDER
DIFFERENT nsPEF TREATMENT CONDITIONS
Condition

E (kV/cm)

T(ns)

1
4
2
7
3
5
6
8

10
20
10
40
10
20
20
40

300
300
300
300
300
300
300
300

n
10
10
100
10
300
100
300
100

9

40

300

300

ExVn

CD31

9480
18960
30000
37920
51962
60000
103800
120000
207600

13
12
10
11
17
25
15
24
13

77
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FIGURE 49 - The plot of CD31 under 9 different nsPEF Tx conditions against the indicated X-axis formula.

TABLE VI -TUMOR VOLUME CHANGES UNDER DIFFERENT NSPEF
TREATMENT CONDITIONS
Condition

E (kV/cm)

T(ns)

n

EtVn

1
4
2
7
3
5
6
8

10
20
10
40
10
20
20
40

300
300
300
300
300
300
300
300

10
10
100
10
300
100
300
100

9

40

300

300

9480
18960
30000
37920
51962
60000
103800
120000
207600

Tumor
volume
(mm3)

132
143
110
101
97
55
45
34
45
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FIGURE 50 - The plot of tumor volume (the mean volume in the first 1-3 days post-treatment) under 9
different nsPEF Tx conditions against the indicated X-axis formula..

Discussion
In these studies the same energy was delivered to two tumors on the same mouse.
One treatment will be called a long pulse (150v, 1 ms, 48 pulses) and the other will be
called the short pulse (6 kV, 300 ns, 100 pulses).
The energy is written as
V2
\Y = T— pf where W is the energy (joule), x is the pulse duration, V is the voltage
R
across the electrodes (volt), R is the tissue resistance (Q), and N is the pulse number.
Though there is not an absolute value of energy, but for long pulse (1 ms) at a lower
voltage (150 V), 48 pulses was calculated to deliver the same energy to the tissue as short
pulse. This was based on differences between electrodes.
Several interesting effects were observed in the study of conventional plasma
membrane electroporation pulses defined as long pulses and nsPEF pulses as described as
short pulses. The first observation indicates that decreases in tumor volumes are observed
in both long and short pulses. However effects of short pulses resulted in greater tumor
size decreases than those observed for long pulses. Furthermore, in studies not shown
here, the long pulse treated tumors rebounded more rapidly than the short pulse treated
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tumors. This indicates that nsPEF treatment of tumors is different than conventional
electroporation pulse treatment and is more effective. Long pulses are known to have
predominant effects on the plasma membrane with little or no effects on intracellular
membrane. In contrast, for shorter pulses, as the pulse duration decreases, greater effects
occur on intracellular membranes. Nevertheless, short pulses have effects on the plasma
membrane to create nanopore formation in a process termed supra-electroportation.
These nanopores are much smaller (~lnm) and more numerous that larger pores formed
by classical plasma membrane electroporation pulses or longer pulses. For 300ns pulses it
is not clear where this condition fits into the paradigms of plasma membrane or
intracellular membrane effects. Based on in vitro effects of long and short pulses on
propidium iodide uptake in Jurkat cells, 60ns pulses had significantly delayed effect on PI
uptake compare to 300ns pulses, suggesting the absence of direct effects on plasma
membranes with shorter pulses and more likely due to biological effects, which could be
related to apoptosis. In addition, PI may be too large to enter nanopores caused by supraelectropoation. For 300ns pulses in this same paper, there were immediate effects as well
as delayed effects on PI uptake, suggesting a mixture of classical plasma membrane
electroporation and supra-electroporation. In contrast, 10 and 100 us pulses caused
immediate PI uptake, suggesting conventional electroporation effects. It should be noted
that effects of these pulses in vitro and vivo may be different and that pulses in the
referenced study were not corrected for energy density. Nevertheless, this provides an
initial understanding of differences between conventional plasma membrane
electroporation and nsPEF yielding supr-electroporation.
A second interesting observation occurred for effects of long and short pulses on GFP
fluorescence.. The long pulses had immediate effects on GFP causing a rapid quenching
effect in minutes. This suggests a direct effect of the long pulses on GFP fluorescence
(quenching). In contrast, the short pulses had significantly delayed effects on quenching
that were coincident with caspase activation, suggesting the GFP protein was turned-over
like other proteins during apoptosis progression.
Finally, the relationships for tumor volume, caspase activation, and micro-vessel
formation were not linear with the formula found for in vivo effects, which scaled with
the produce of the pulse duration, electric field, and square root on the pulse number.
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This is not surprising since the square root of pulse number is related to the random walk
hypothesis. Random walk would be operative in vivo as cells rotate in solution, thus
experience pulses from several angles. Such rotation would not be present in vivo tissues.
Therefore the randum walk hypothesis would not apply in vivo.
In summary, long and short pulses differ in effects on tumor growth and GFP
fluorescence (quenching). Short nsPEF pulses have lesser or delayed effects on GFP
quenching and great effects on decreases in tumor size. It is likely that long pulses have
direct effects on GFP quenching, while short pulses have quenching effects that are
coincident with protein turn-over during apoptosis progression. In addition, the scaling
law defined for in vitro effects on calcium mobilization and platelet activation does not
hold for caspase activation, micro-vessel formation and tumor size decreases in tumor
tissues in vivo. This is expected based on the absence of a random walk effect in vivo.
However, for some of these studies, the small replicate number indicates a need for more
trials to substantiate the dose-effect scaling law or some other coefficients relating nsPEF
conditions and biological effects in vivo.
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CHAPTER VII

CONCLUSIONS
NsPE have been previously used for military and industrial decontamination
purposes. NsPEF application in biology gave birth to bio-electrics, which applies ultrashort nsPEF to biological living cells, tissues, organs, and living systems. According to
the previous modeling research and in vitro studies, the main characteristics of
nanosecond pulsed electric fields are their high power and low energy density leading to
very little heat production and their special ability to permeabilize intracellular
membranes and organelles. The effects of nsPEF Tx on tissues or humans had not been
tested until very recently. Initial studies were done ex vivo on mouse embryonic
fibroblasts. Fibrosarcoma tumors were injected in the flanks of C57B16 mice, treated ex
vivo. Treatment of the fibrosarcoma B10.2 cells indicated a reduced size after nsPEF
treatment. Results from ex vivo studies indicated caspase activation and induction of
DNA fragmentation define by TUNEL. The present studies are based on these initial
studies and confirm that nsPEF Tx has the potential to effectively eliminate tumors. In
addition the mechanisms of nsPEF effects on B16fl0 tumors in vivo are revealed.
Transillumination and surface photography showed a consistently decreasing tumor
size and eventual self destruction in the treated tumor compared with the untreated
melanoma, which kept growing throughout the experiment protocol period. After nsPEF
Tx, tumor development was inhibited with sharply decreased volumes on the first 7 days
post-nsPEF Tx as compared to control tumors (/?<0.05). The nsPEF treated tumor weight
was reduced to 14.8% of the control group (p<0,01). H&E and TEM images both
showed that without nsPEF Tx, the melanomas kept a regular outline of tumor cells with a
pale nucleus and prominent round nucleolus. Cell cytoplasm was finely dusted with
melanin and the cells often formed tumor nests with an active growing center marked by
a good blood vessel network and well-organized cancer cell cords marked by invading
vessels, dermis and or muscle fibers. In nsPEF treated melanomas, solid tumor nest
construction was detached, tumor cords were broken and the space between tumor cells
enlarged with shrinking spindle shaped nuclei inside. Regression in size of tumors
occurred within 24 hours with surrounding tissue swelling and bleeding. Subcutaneous
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tissue and skin were recovered within 7 days. Skin pulsed with nsPEFs produces typical
inflammation in the treated area during the first three days but can be resolved in one
week. Fontana-Masson stain indicates nsPEF can externalize the melanin. Iron stain
suggests nsPEF caused slight to mild hemorrhage in the treated tissue. Histology
confirmed that repeated applications of nsPEF did not damage the peripheral healthy skin
tissue of treated mice.
NsPEF Tx can significantly reduce subcutaneous murine melanoma development
producing tumor contraction and nuclear shrinkage while concurrently but not
permanently damaging peripheral healthy skin tissue in the treated area. Furthermore,
these studies revealed the mechanisms of nsPEF-induced tumor demise, which included
DNA damage as defined by Histone 2AX phosphorylation, apoptosis induction as
defined by caspase activation and DNA fragmentation as well as tumor infarction as
defined by loss of blood supply to the tumor and the discovory of changes in blood vessel
density as defined by CDs 31, 34, and 105, which are markers for large, medium, a
micro-vessel formation. Therefore, nsPEF Tx can be used as a highly localized and drugfree, non-thermal physical technique for tumor therapy with known mechanisms of
action. Thus these studies pave the way for a fully comprehensive understanding of
applications for nsPEF.
NsPEF treated melanomas showed double stranded DNA breaks; H2AX activation
appeared 1 h after the nsPEF treatment. At 3 hours post-nsPEF Tx, H2AX climbed to a
peak and caspases were activated. Caspase enzymes reached their climax at 6 hours postnsPEF Tx. TUNEL detected apoptosis from 3 hours post-nsPEF Tx and the maximum
appeared at 6 hours post-nsPEF Tx. Histological examination of nuclear morphological
confirmed the same time sequence of changes seen in caspase and TUNEL assays.
Western blot showed BAD expression increased while Bcl-2 expression decreased
throughout the post-nsPEF Tx hours. NsPEF treatment activated caspase 9. These data
suggest that nsPEF can affect melanoma by inducting apoptosis. A likely conclusion
indicates that nsPEF treatment triggered a chain reaction: breaking double stranded
DNA, initiating H2AX phosphorylation for repair, thereby activating caspases and
initiating increased Bad and decreased bcl-2 expression resulting in apoptosis with
mitochondria involvement. The treated melanomas self destruct as evidenced by
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histological changes and the long term study. These results demonstrated that nsPEF Tx
induces apoptosis in a time-dependent manner in melanomas in vivo.
Both histology and intratumoral MVD assessed by CD31, CD34 and CD 105 showed
a significant lower vessel number and density in the nsPEF Tx group when compared to
the control group. The inhibition rates were 76.9%, 66.7% and 39.9% by CD31, CD34
and CD 105, respectively. Western blot indicated protein expression of VEGF and PDECGF was lower in the treated melanoma than that in control tumors. The data suggest
that nsPEF Tx directly damaged the melanoma cells and pre-existing blood vessels. As a
result, tumor-derived blood vessel growth-stimulating factors such as VEGF and PDECGF decreased. The balance between pro-angiogenic and anti-angiogenic cytokines
was broken and new vessel formation was inhibited which contributed to the tumor self
destruction. It is concluded that direct vascular damage on the pre-existing vessels and
anti-angiogenic effects on neovasculature are another possible mechanism for tumor selfdestruction after nsPEF Tx.
A five-month in vivo survival study of tumors exposed to nsPEF tested the long-term
effect. All 17 mice in the treated group survived 3-5 months with the melanomas in
complete remission while 14 of the 19 control mice died within 3 weeks due to fast tumor
growth and big tumor volumes. Tumor volume, survival times and tumor vessel numbers
were statistically different (p<0.00\) between control and treatment groups. Both groups
had one case of tumor metastasis but no significant difference existed in tumor metastasis
between the groups. In vivo images and H&E staining revealed nsPEFs initially disrupt
and finally destroy tumor construction and blood supply. IHC and tissue micro-array
showed that CD31, a marker for micro vessel density, decreased significantly after nsPEF
Tx and western blot analysis confirmed this reduced CD31 protein expression. After the
5-month long survival observation no tumor recurred at the primary site. Therefore
nsPEF Tx is safe over a 5-month period.
Initial studies on cells in vitro showed that there was a relationship between nsPEF
conditions and biological effects that followed the formula: biological response = ET Vn,
where E=energy density, x= pulse duration, and n= pulse number. Our data in vivo
showed that this scaling law relationship did not hold for tumor tissue response in vivo.
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The possible reason is tumor tissues are fixed and the random motion effects which exist
in cells in media are not present in vivo.
This study is the most thorough and systematic animal trial for the nsPEF application
in solid tumor in vivo. NsPEF Tx induced effects were different from ionization or
heating, it can produce broad impacts on the melanomas in vivo, ranging from DNA
fragmentation, caspase activation, nuclear damage, apoptosis induction, pre-existing local
vessel damage, intra-tumoral neovascular inhabitation to systematic histological changes
both in short- and long-term experiments. The data reveals nsPEFs act as non-chemical,
non-thermal, and non-ligand stimuli that can treat melanomas in vivo.
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APPENDIX
Abbreviations
Abbreviations

The full name

3T3
AT
BS
BS-LCL
DMEM
DTIC
FA
FDA
GFP
H&E
HCT116
HeLa
HL-60
HS578T (BrCa)
IL-2
IACUC
IHC
JURKAT
NsPEFTx
PD-ECGF
PVDF
SV40

Mouse pre-adipocytes
ataxia-telangiectasia
Bloom syndrome
B-cell lymphoblastoid
Dulbecco's modified Eagle's medium
decarbonizes
Fanconi's anemia
United States Food and Drug Administration
green fluorescent protein
hematoxylin & eosin stain
human colon carcinoma cells
Human adenocarcinoma of the cervix
human promyelocytic leukemia cells
Human ductal breast carcinoma
Interleukin-2
The Institutional Animal Care and Use Committee
Immunohistochemistry
human, peripheral blood, leukemia, T cell
nanosecond pulsed electric fields treatment
platelet-derived endothelial cell growth factoOr
polyvinylidene difluoride
Simian virus 40

TdT

terminal desoxynucleotidyl transferase

TEM
TUNEL

transmission electron microscopy
Terminal deoxynucleotidyl Transferase Biotin-dUTP Nick End
Labeling

VEGF
XP
z-IETD-FMK

vascular endothelial growth factor
xeroderma pigmentosum
Z-Ile-Glu-Thr-Asp-fluoromethyl ketone
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